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 130 
KF Ring  Kayser Fleischer Ring  
PT Prothrombin Time 
INR  International Normalized  Ratio  
GABA  Gamma Amino Butyric Acid   
WHC West Haven classification 
EEG  Electroencephalography  
PHES  Psychometric hepatic encephalopathy score  
NCT  Number connection test  
SBP  Spontaneous bacterial peritonitis 
EVL  Endoscopic variceal ligation 
 131 
CONTENTS 
Sl.No. TITLE Page No. 
1. INTRODUCTION 1 
2. AIMS AND OBJECTIVES 3 
3. REVIEW OF LITERATURE 4 
4. MATERIALS AND METHODS 74 
5. OBSERVATIONS AND RESULTS 80 
6. DISCUSSIONS 100 
7. CONCLUSIONS 104 
BIBLIOGRAPHY 
ANNEXURES 
PROFORMA 
ETHICAL COMMITTEE APPROVAL ORDER 
CONSENT FORM 
PATIENT INFORMATION SHEET 
KEY TO MASTER CHART 
MASTER CHART 
TURNITIN-PLAGIARISM SCREEN SHOT 
DIGITAL RECEIPT 
CHI-SQUARE TEST 
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1
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2       
OBJECTIVE /AIM: 
The purpose of this study to assess serum Zinc levels in DCLD patients with 
various stage of hepatic encephalopathy and determine the role of Zinc 
deficiency in precipitation of hepatic encephalopathy. 
MATERIAL AND METHODS: 
The descriptive cross sectional study was conducted at Rajiv Gandhi 
Government General Hospital and Madras Medical College Chennai   
Total 75 cases, all patients above 20 year of age, both sex and diagnosed cases 
of DCLD, admitted in hepatic encephalopathy. All cases were further evaluated 
for serum Zinc and all patients were divided according to stage of hepatic 
encephalopathy and class of liver cirrhosis. The data was analyzed with 
statically soft ware (SPSS) and the p-value <0.001 was considered as statically 
significant. 
RESULT: 
In our study showed 96% male and 4% female, predominantly affected group 
between 30-50 year of age (63%). Most common aetiology was alcohol abuse 
(90%), more than 10 year duration. All DCLD patients in HE had low serum 
Zinc, low serum Zinc significantly associated with worse grade of HE and 
advanced class of liver cirrhosis (p-value 0.001). Our study also shown those 
patients have low serum albumin significantly associated with low serum Zinc 
(p-value 0.029) 
 
CONCLUSION: 
The inferences attained from the study are all patients in DCLD with hepatic 
encephalopathy identified low serum Zinc. More drops in serum Zinc is 
correlated with worse grade of HE, low serum Zn indirect precipitating factor of 
HE. Low Zn level also associated with higher class of cirrhosis and low albumin   
Short term Zn supplementation may be useful in prevention and treatment in HE 
patients. 
Key Words: 
Decompensate Chronic Liver Disease (DCLD) 
Hepatic encephalopathy (HE) 
Serum Zinc 
Albumin  
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INTRODUCTION    
 Liver disease affects millions of people worldwide every 
day. In developing countries like India, cost of health care has 
always been an issue.  
 Chronic disease like liver cirrhosis and its complication are a 
major health problem, in India ,where large population are living 
with poverty, poor hygienic environment , lack of education . 
Burden of cirrhosis patients is keep on increasing; most of the 
patients are admitted in hospital with complication of cirrhosis.  
 Cirrhosis is defined anatomically as a diffuse process with 
fibrosis and nodule formation. It is the end result of the fibro 
genesis that occurs with chronic liver injury 
1 
 Diffuse fibrosis cause architecture distortion with 
regenerative nodule formation results in decreased liver cell mass 
and reduced blood flow to the liver.
1,2
  
In India
 
most common cause of cirrhosis is alcohol abuse and 
viral hepatitis. Reversible fibrosis with ongoing injury in course of 
time develop a decompensate condition (DCLD) that associated one 
or more complication like ascites, jaundice, Hepatic 
encephalopathy& UGI bleed. 
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Hepatic encephalopathy (HE)  a life threatening complication 
that can be occur in  acute or chronic liver failure .About 30% 
patient  of cirrhosis die due to hepatic coma .
5
HE in  patient of liver 
failure is an indication of poor prognosis, in a cirrhotic patient HE 
develop due to one or more precipitating factor or due to fulminate 
liver failure or it could be a result of prolonged portal systemic 
shunting . 
Hepatic encephalopathy probably due to gut derived 
neurotoxin such as ammonia. Other key factors are astrocytes 
dysfunction, disturbed neurotransmitter regulation and oxidative 
stress developed in astrocytes. 
Zinc is an essential trace element ,second most abundant trace 
element in the body .Zn is associated with more than 300 enzymatic 
system 
7
 It is an important co –factor in urea cycle, have a great 
role in conversation of ammonia to urea .Zn increase the natural 
defense of reactive oxygen radical, Zn also act as an antioxidant 
,anti apoptotic agent ,co- factor for DNA synthesis and an anti 
inflammatory agent .So deficient Zn levels seems to have effect in 
pathogenesis  of Hepatic encephalopathy. 
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AIM AND OBJECTIVES OF STUDY 
Aim of this study observe serum zinc level in DCLD patient 
with various stages of hepatic encephalopathy and determine the 
role of zinc deficiency in precipitation HE .Study  will also 
describe  association of  zinc deficiency according child‟s Pugh 
class, level of albumin and  anorexia, malnutrition, vomiting, 
diarrhea, age, duration of alcohol intake in DCLD patient.  
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REVEIW OF LITERTURE  
GENERAL CONSIDERATION   
Cirrhosis is defined as anatomically as a diffuse process with 
fibrosis and nodule formation, due to various etiology.
1,14
 Cirrhosis 
is dispersed septal fibrosis of the liver, associated with regenerative 
parenchymal nodules formation and forms fibrous sheets which are 
links portal tracts and central zones. Cirrhosis results from 
prolonged and hepato-cellular necrosis due to various reasons
14
. 
 
Figure1- Cirrhosis-fibrosis with nodules formation 
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These diseases should be detected as early as possible, 
fibrosis alone cannot say cirrhosis, and Formation of nodule in 
absence of fibrosis as in partial transformation is not cirrhosis.  
CAUSE OF CIRRHOSIS
1, 2
 
1) Alcohol abuse 
2) Chronic viral hepatitis (B,C and D ) 
3) NSAH (Non alcoholic steatohepatitis) 
4) Metabolic causes; 
a. Copper over load (Wilson disease)    
b. Type 4 glycogenesis 
c. α 1 antitrypsin deficiency  
d. Iron over load (Haemochromatosis)        
e.  Galactosaemia  
f. Cystic fibrosis 
g.  Glycogen storage disease 
5) Biliary Tract Disease  
a.  Extra hepatic biliary obstruction  
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b. Intra hepatic biliary obstruction 
c. Primary biliary cirrhosis 
6) Auto immune hepatitis  
7) Primary Sclerosing cholangitis 
8) Hepatic venous out flow block – Heart failure  
                                               Budd –chiari syndrome 
9) Toxin and drug e.g.; Methotrexate,amiodrone   
In developing world main cause is viral hepatitis, but alcohol 
and autoimmune condition may be increasing. 
 In western countries alcoholic abuse most common cause of 
DCLD but NASH (Non alcoholic cirrhosis) and viral cirrhosis 
(particular hepatitis C) are increasing.   
EPIDEMIOLOGY  
Chronic liver disease and cirrhosis causes 30000-450000 
deaths each year in India.  
Many patient die from the disease in the fourth to fifth decade 
of the life. Most of death due to complication of DCLD, Each year 
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additional 4000 deaths are attributed to Acute Fulminate Liver 
Failure (FLF).  
FLF may be caused by viral hepatitis (B, C&E), Drugs and 
Toxin induced (e.g. acetaminophen, cabon tetrachloride, 
Amanitaphalloid), Auto immune hepatitis, Wilson‟s disease etc , 9    
patient with FLF have 50-80% mortality rate. One third patient of 
FLF due to unknown etiology 
ETIOLOGY IN INDIA
9,10
  
Common cause of cirrhosis in India  
 Alcoholic Liver Disease (35%)  
 Post infectious causes (30%)  
 Unknown causes (18%)  
 Post Hepatic & Biliary causes (8%)  
 Miscellaneous (9%)  
Risk factor associated with cirrhosis  also depend on
11
  
1) Age  
2) Sex  
3) Duration of disease  
 8 
4) Diabetic mellitus  
5) Poor immunological status 
6) Life style 
 
. 
Figure2- Major Risk for cirrhosis 
 
The terms compensate and decompensate generally used for 
cirrhosis. Some words about terms-  
COMPENSATED CIRRHOSIS
16, 18
 
Compensated cirrhosis can be symptomatic or asymptomatic. 
Mostly without any sign and symptom of liver failure, patient 
diagnose during routine screening or at operation time. Liver injury 
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on going in this stage but it is reversible in nature, due to response 
of liver injury healing process will start known as fibrogenesis.  
It started by activation of stellate cell due to secretion of 
cytokines, fibrosis may be progress and can become irreversible if 
not treat it at time
16
.in this stage firm hepatomegaly  and mild 
spleen may present, some sign like ankle swelling, vascular spider 
palmer erythema can be occur, liver function may be quite within 
normal range in this group, most of  time mildly elevation in serum 
transaminase or gamma –glutamyl transpeptidase concentration, 
confirmation of cirrhosis by liver biopsy and liver imaging , liver 
biopsy confirmatory gold standard test,
14,15
 compensated phase can 
be precipitate by excessive alcohol intake, drugs , infection and 
trauma, mild portal hyper tension may present in this stage without 
liver function abnormality , We can  treat patient successfully and 
completely by removing causative agent and liver protective 
medication, by early diagnosis and by measuring the viral load we 
can control HBV and HCV  induced liver cirrhosis also. 
 10 
 
Figure: 3- Cellular and matrix change after chronic liver injury 
 
DECOMPENSATED CIRRHOSIS
1, 24
; 
Ongoing liver injury and fibro genesis in decompensate stage 
patient develop bridging fibrosis and nodules formation. 
Fibrosis can be centrilobular ,periportal or pericellular,  After 
a advanced fibrosis liver architecture disruption may occur, 
development of portal hypertension most common complication of 
decompensation, appears in form of ascit es as a first sign of 
decompensation. 
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The patient  in this condition need hospitalization due to 
complication of progressive cirrhosis like ascites, jaundice ,or 
gastrointestinal bleeding and other serious complications of liver 
failure, like  hepatic encephalopathy ,hepatorenal  syndrome 
,hyponatremia  and spontaneous bacterial peritonitis. General 
health poor with weakness, muscle wasting and weight loss.  
Continuous low grade fever (37.5 -38
0
c) caused by gram 
negative bactraemia, continuous ongoing hepatitis lead to liver 
necrosis.  
Ongoing alcoholic hepatitis leads to end stage as 
hepatocellular carcinoma. Jaundice indicate that active liver cell 
destruction more than the regeneration capacity, severity of 
jaundice is always alarming sign, severe jaundice indicate more 
loss of liver function   and acute liver failure in chronic cirrhosis.  
Other manifestations like skin pigmentation, clubbing, 
purpura may associated with decrease  platelets counts, patients 
may have hypotension  loss body hair, vascular spiders, Erythema 
on hands, dupuytrens contracture, discoloration of  nails and genital 
atrophy, enlargement of parotid glands and gyanecomastia are 
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common in DCLD. Pallor due to UGI bleeding, flapping tremor in 
HE.  
The liver may be enlarged, if enlarged than smooth surface, 
firm and regular edge in initial stage but in advanced CLD liver 
usually shrunken and impalpable. The spleen commonly palpable 
may be moderate to severe enlarged, most of complication due to 
hyper dynamic flow of blood and vasodilation
21
 Cirrhosis broadly 
divided in alcoholic cirrhosis, chronic viral cirrhosis due to 
hepatitis B and C, biliary cirrhosis and others. 
PATHOPHYSIOLOGY OF CIRRHOSIS 
The liver cirrhosis occurs due to change in the normally well 
maintain processes of extracellular matrix formation and 
degradation. The usual scaffolding for liver cells are formed by of 
collagens ( type I,II III, V, ) proteoglycans , glycoprotein and 
matrix cellular protein .All component of extracellur matrix 
maintain the function of  hepatocytes, Stellate cells, situated in the 
peri-sinusoidal have important role for formation  of extracellular 
matrix.  
Stellate cells (Ito cells) may become activated after chronic 
liver injury. Activation of stellate cell occur in two phase ,first 
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initial phase occur due to paracine stimuli and prolongation stage 
due to paracrine and autocrine stimulation during perpetuation 
stage of stellate cell many change occur in cell behavior lead to 
proliferation, secretion chemotaxic agent, fibro genesis, 
contractility of hepatic cell. 
ECM degradation, inflammatory and immune response, by the 
initiation of these stellate cell change into collagen producing cells 
by various paracrine factors released by hepatocytes and kupper 
cells. Like TGFβ1, MMP-2, MCP-1, PGDF and ET 
 
Figure: 4 -Liver stellate cell activation due to  
response of liver injury 
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The mediators after these effect shown various change in 
behavior of stellate cell , platelets  and sinusoidal endothelium cell 
after chronic liver injury e.g. Increased cytokines(TGFβ1) 
transforming growth factor β 1 is found in patients with chronic 
hepatitis C and  Cirrhosis.
22
 TGF β 1 release  activate stellate cells 
to produce type 1 collagen formation , that excessive collagen 
deposition in the space of Disse  and the decreased  size of 
endothelial fenestrate that  increase  the Capillarisation of 
sinusoids. Activated stellate cells also have contractile properties. 
Both capillarisation and constriction of the sinusoids cell due to the 
stellate cells lead to the development of portal hypertension. In 
future, treatment to prevent fibrosis should focus on decreasing 
hepatic inflammation, avoid the activation of stellate cells, blocking 
the fibrogenic agent and fibrogenic activity of stellate cell .
30,31
 
HISTOPATHOLOGY:  
 
The typical histological feature of cirrhosis is diffuse liver 
fibrosis and regenerative hepatic nodules formation.  
With micro nodular cirrhosis the nodules are uniformly small 
and similar in size to liver lobules.  
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In macro-nodular cirrhosis the nodules are hetrogenous in 
size and may be more than10mm.  
It may not be visible on needle biopsy as complete nodule 
formation. Other features like fragmentation and pattern of fibrosis 
on reticular staining suggest the proper diagnosis.   
Cell necrosis is the evidence of active regeneration and 
cellular infiltrate shows etiological agent is still survives in liver 
cell and destruction is ongoing.  
Whenever we are taking the biopsy from the histological 
specimen, the biopsy should be from the nodules. Open biopsy in 
Laparoscopic examination gives good results  
Endoscopic guided biopsy is also a good option for 
histological diagnosis but that is under development phase. 
 Biopsy very useful in undiagnosed etiology of cirrhosis
14, 15
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Figure : 5- Histopathology of cirrhosis of liver showing fibrosis 
and nodules of regenration in hepatocytes 
 CLINICAL FEATURES  
Many cases cirrhosis may be incidentally found without 
symptoms or signs during at routine examination. An evidence of 
the presence of cirrhosis and its etiology usually comes after 
complete history.  
SYMPTOMS  
 Jaundice is can be absent in cirrhosis. If jaundice present that  
suggests either the causative agent is still active, that ongoing 
injury is reason for decompensation, or a drug toxicity might 
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have caused further impairment liver function that cause 
elevation of bilirubin levels
1,2
.  
 Easy fatigue ability, tiredness, weakness or breathing 
difficulty are common and contributes to the poor general 
health in cirrhosis patients. Anorexia present commonly occur 
cases of cirrhosis, When present it is an alarming sign of liver 
failure. Weight loss is seen in end stage liver disease
37
.  
 Nausea and Vomiting are very common. A remediable cause 
should be come first. Vomiting may be in form of upper UGI 
bleeding, content should be examined to rule out 
haematemesis.  
 Abdominal pain or discomfort is common, pain present in the 
right upper quadrant or right lower ribs. Ill-defined vague 
pain and generalized abdomen discomfort due to distention 
caused by ascites  
 Constipation or loose stools, both may occur in cirrhotic 
patient, both can be precipitate the complication of cirrhosis.  
 Abdominal hernia occur with ascites ,water and salt  retention 
leads volume overload state can occur as  edema of ankles 
and legs.  
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 Pruritis is an important diagnostic clue for primary biliary 
cirrhosis. 
  Difficulty in breathing may be associated with massive 
ascites. In Some patient of cirrhosis, dyspnoea may be 
associated with fibrosing alveolitis, pulmonary shunting, 
pulmonary hypertension and Hepatic-pulmonary 
syndrome
39,40
 
 Patient of liver cirrhosis develop spontaneous bleeding from 
the gums or nose. UGI bleeding present i n form of 
hemetemesis and malena. Coagulopathy can be occur severe 
liver failure.  
 Neurological complication of DCLD like hepatic 
encephalopathy. Due to failure of urea cycle in liver lead to 
increase ammonia level affect the brain. HE also sign of 
fulminate hepatic failure, most common cause to 
hospitalization of cirrhotic patient, Depression is common.  
 Fever can present as a symptom spontaneous bacterial 
peritonitis common may have no obvious cause.  
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PHYSICAL SIGNS  
 Most patients with cirrhosis look poor built, with the late 
stage liver disease, muscle wasting and loss of adipose tissue 
commonly from face and neck occur bone may become 
prominent known as cirrhotic faces
38
.  
 An acute worsening of nutritional appearance may suggest 
infection or bleeding, while more prolonged deterioration 
results from liver decompensation. Anemia due to bleeding 
from UGI tract or iron deficiency due to prolonged loss of 
blood.  Jaundice suggests liver decompensation and usually 
an alarming sign of fulminate liver failure in CLD patient.  
 Cyanosis is uncommon except there is marked pulmonary 
shunting. Mild shunting is common in cirrhotic. Hypertrophic 
ostoearthropathy may also be present. 
 Skin changes like Spider naevi, Paper money skin43, erythema 
of palm etc are present in cirrhosis more commonly in 
alcoholic cirrhosis. Excessive bruising noted when hepatic 
function deteriorates severely. 
  DCLD patients especially those with hemochromatosis show 
of hyper pigmentation with widespread melanin pigmentation. 
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Vitiligo appears in autoimmune liver disease. Lichen planus 
is associated with primary biliary cirrhosis.  
 Testicular atrophy is common in DCLD mainly in alcoholic 
Cirrhosis or hemochromatosis, Gynaecomatia seen in patient 
who taking spironolactone, patient usually presented with 
loss of pubic and axillary hairs and signs of feminization. 
Manse disturbance common in female44,45, 
  Dupuytren‟s contracture and Parotid enlargement are more 
common in alcoholic cirrhosis. They are sign related to 
alcoholism more than to cirrhosis.  Kayser- Fleischer ring is a 
particular sign to look for in the case of Wilson‟s disease as it 
is a potentially treatable cause.  
ABDOMINAL SIGN  
Abdomen maybe distended due to accumulation of fluid or 
rarely due to enlargement of abdominal organs. Skin over distended 
abdomen may appear dry and rough with prominent veins. Multiple 
dilated veins can be seen. Ascites most is common in DCLD.  
The abdomen appears distended and flanks are full and the 
umbilicus is out ward and everted. Shifting dullness may present. 
Dilated veins may be seen all over the abdominal wall peri-
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umbilical known as caput medusa or dilated vein over the flanks 
indication of Budd -Chiari syndrome.  
Enlarged liver or spleen can increase local bulging of the 
abdomen, a firm cirrhotic liver may be normal or mild enlargement, 
significantly palpable in the early stages, shrunken liver in late 
stages with nodularity.  
Measurement of the liver span is helpful in diagnosis of 
shrunken liver.  
The normal range is 12-16 cm. (average 14 cm); a contracted 
liver is easily picked up by USG. Abdomen percussion is helpful in 
diagnosis of ascites Auscultation may useful for clinical diagnosis 
of a Liver bruit for large hepatoma or a venous hum  indicates 
portal Hypertension. A friction rub over the hepatic area indicate 
hepatocellular carcinoma. A continuous venous hum heard over the 
epigastrium known as Baumgartner sign.  
In enlarged veins the direction of flow should be determined. 
The Presence of the veins and their position should be marked.  
The presence / absence of lower leg swelling are also very 
important differential clue in between occlusive disease of veins 
and Budd Chiari syndrome. 
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INVESTIGATION  
Total Blood Count  
Routine hematological values can be normal in all cirrhotic 
patients.  
Low hemoglobin is common. Normocytic normochromic 
anemia on blood films target cells may be seen and in acanthocytes 
may see rarely in alcoholic cirrhosis and other features of 
haemolysis may be seen. The White Cell count tends to low in 
cirrhosis patient due to hypersplenism.  
If white cell count is raised an indication of infection should 
be take seriously. The platelet count is usually low in the cirrhotic 
due to hypersplenism. Liver cell injury decrease production of 
Coagulation factor in liver, coagulation factors usually low in 
advanced liver cirrhosis. Vitamin k depended factors 2, 7, 9, 10 are 
commonly affected. Factor VII is the most affected and earliest 
changes also occur in factor 7concentration in cirrhosis.  
Prothrombin time is prolonged in decompensated cirrhotic  
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BIOCHEMICAL TESTS  
Liver Function Test 
Liver function test limited role in cirrhosis, as it may be 
normal. AST and ALT can be normal or high in cirrhosis if 
causative factor  is no longer active and enzymes can come to 
normal with effective therapy,(like Interferon, Ribavarine). In 
alcoholic cirrhosis liver enzymes usually elevated, AST/ALT ratio 
is usually greater than 2.  
In most patients‟s serum alkaline phosphatase usually 
elevated about two times to normal except in biliary cirrhosis there 
level more raised. The gamma glutamyl transferase and serum 
transaminase level elevated in alcoholic cirrhosis.
51, 52 
 The serum 
total bilirubin level is can be normal in early stage of cirrhosis . But 
in decompensation stage bilirubin will be increased, other cause of 
increased bilirubin load in DCLD patient due to haemolysis, UGI 
bleed, and certain drugs like steroids. A raised in bilirubin without 
any obvious cause suggest hepatic decompensation.  
Low serum protein and serum albumin levels are usually 
present in DCLD, synthesis of albumin reduced in cirrhosis patient. 
However hypoalbuminea also due to extracellular fluid volume 
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expansion or due to gastric causes (poor intake, malnutrition) or 
renal pathology also can associate with low albumin level.  
RENAL FUNCTION TEST  
Plasma electrolytes disturbance usually associated with   
cirrhosis and patient need close monitoring. Hyponatremia is most 
common usually due to reduction of free water solute clearance and 
total body water intake, hyponatremia may be due to salt loss due 
to diuretic therapy it is important risk factor for hepatic 
encephalopathy
47
. Hypernatremia is less common in cirrhosis 
patient and may occur with GI bleed, excessive use of lactulose and 
with severe fluid restriction. Serum potassium is usually normal in 
cirrhotic patients. But both hyper and hypokalemia can occur 
depending upon the type of diuretic use for treatment 
E.g.spironolactone produces hyperkalemia, while loop diuretics like 
furesemide produces hypokalemia. Urine sodium and potassium 
monitoring are useful to decide diuretic therapy. Spironolectone 
serious side effect is hyperkalemia, we can increase the dose of 
spironolactone till the urine sodium/potassium ratio is more than 
one.  Hypomagnesaemia and Hypophosphatemia are also common 
occur in alcoholic patient with cirrhosis. The electrolyte 
abnormality can precipitate DCLD complication should be 
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diagnosed and treated as early as possible. In well compensated 
cirrhosis, the urea level is normal but it may be low or high once 
decompensation occurs due to disturbance in urea cycle in liver. So 
renal failure in cirrhosis should be monitors by serum creatinine. 
Renal failure in cirrhosis patient is common due to diuretics over 
use, hypotension hepatorenal syndrome etc. Fasting blood glucose 
is usually low. 
But most of the cirrhosis are insulin resistant and have post 
prandial hyperglycemia .The serum cholesterol free triglyceride 
level increase in cirrhotic patient.  
SERUM MICRO ELEMENTS LEVEL IN DCLD PATIENT; 
Patient with advanced cirrhosis serum zinc level usually low. 
Low level in DCLD associated hypoproteinemea, and also due to 
use of diuretic that cause excessive discharge from urine, that level 
more low HE.  
Malnutrition and poor oral intake may also relate to zinc low 
level. Zinc have important co-factor of urea cycle enzymes .that can 
lead to failure urea cycle as the result this blood ammonia level will 
be increase, that is a important pathogenesis of HE in cirrhotic 
patient . Zn level more low with increase stage of hepatic 
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encephalopathy .manganese level usually high in DCLD patient 
.both Mn and Zn are have important role in DCLD related 
complication. 
ANATOMICAL AND PATHOLOGICAL DIAGNOSIS  
The diagnosis of cirrhosis depends on demonstrating 
widespread fibrosis in the liver combined with nodules.  
THIS MAY BE DIAGNOSED BY  
 
1) Laparoscopy: direct visualizes the liver and enables direct 
biopsy.  
2) Ultrasound abdomen: is suggested by dense reflective areas 
of irregular distribution and increased echogenicity. Shrunken 
liver and spleenomegaly commonly occur in DCLC. However 
ultrasound is not reliable for diagnosis unless ascites is 
present.  
3) CT scan: Liver size can better assessed and usually irregular 
nodular surface seen. Hepatic and portal  vessels can be 
imagined with contrast. Ascites can be seen and gall stone 
can be visualized.  
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4) Liver Biopsy: Reticular and collagen stains are need to 
highlight the fibrosis. Liver cell size in variable size and 
shape in cirrhosis and presence of nodules with fibrous septa 
important clue in diagnosis.  
5) Radioiso top scaning; in experimental phase.  
INVESTIGATION FOR ETIOLOGICAL DIAGNOSIS  
It is important to establish the causative agent of cirrhosis. 
The following investigation may be useful  
1) Serology of viral hepatitis:  
 HBsAg  
 IgM and IgG anti HBV Antibody  
 IgM AND IgG anti HCV antibody  
 HCV RNA titer  
 Liver biopsy  
 Hepatitis B Viral load 
2) Serum Iron and Hepatic Iron content to rule out 
hemochromatosis.  
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3) Eye examination for KF ring by slit lamp and serum 
ceruloplasmin  and serum and urinary copper to rule out 
Wilson‟s disease  
4) Anti Smooth Muscle Antibody  
5) Anti LKM Antibody  
6) Anti-mitochondrial Antibody  
7) Serum α – Fetoprotein to rule out hepatocellular malignancy  
COMPLICATION OF DCLD  
Major complications  
1) Portal Hypertension- This is the major complication of 
cirrhosis but these can be occur due to by extra hepatic portal 
vein thrombosis or  Non cirrhotic portal fibrosis.  
2) Ascites- Abdominal distension also very common 
presentation of DCLD  
3) Hepatic Encephalopathy- Major Cause of sensorial 
disturbance and unconsciousness in DCLD patients. 
Encephalopathy can be caused by other metabolic process 
also should be rule out in DCLD.   
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4) Hepatocellular carcinoma-  Serious complication of  
cirrhosis with very poor prognosis  
5) Infection- Spontaneous bacterial peritonitis an important 
cause for sudden deterioration of cirrhosis patient, occur with 
low grade fiver and abdominal pain. Most common due to 
gram negative bacteria.    
UGI BLEEDING  
Associated with portal hypertension and peptic ulcer disease 
in alcohol cirrhosis, may occur due to varices develop in esophagus 
and hemorrhoids. 
OTHER COMPLICATIONS  
1) Anemia & Haemolysis  
2) Fluid electrolyte disturbance  
3) Hepatopulmonary Syndrome  
4) Hepatorenal Syndrome  
5) Hepatopulmonary Syndrome  
6) Gallstones  
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Figure: 6- Complication in cirrhosis patient  
due to hyper dynamic circulation 
PROGNOSTIC INDICATORS  
Child –Trucot  Pugh score58,59; 
Table1- Child-Pugh classification  
 
Class A score=5-6, Class B score=7-9, Class C score=10-15  
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2. MELD SCORE
60
[Model for end stage liver disease]; 
It was develop for need of TIPS in cirrhotic patient, depend on  
1) Serum Bilirubin 
2) Serum Creatinine 
3) Prothrombin time(INR) 
Important use of MELD score for liver transplant listing and 
short out for Priority of liver transplant 
 
Cox Regression Model  
Poor prognosis is associated with:  
 Marked Ascites   
 Prolonged PT and elevated INR 
 Gastrointestinal Bleeding  
 Old Age  
 High Serum Bilirubin  
 Continuing Alcohol Consumption  
 Spontaneous Bacterial Peritonitis  
 Neurological complication   
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 Etiology 
 Liver size; enlarged liver good prognostic sign  
 Portal venous pressure persistent low blood pressure (systolic       
BP less than 100mmhg) 
 
TREATMENT:  
 
The management of reversible fatty liver is focused towards 
early pick up of liver fibrosis. An adequate balanced diet and 
abstinence from alcohol are essential. A balanced diet of 1-1.5 g of 
Protein per kg of body weight is adequate. Liver- protectives are 
not very much helpful.   
DCLD patients with volume overloaded state like edema and 
ascites should be treated with   
1) low salt diet 
2) Fluid restriction.  
3) Diuretics. 
Specific treatments to prevent complication like lactulose for 
soft and free stool to prevent hepatic encephalopathy, treatment for 
portal hypertension, gut stabilizer like Rifaxamine or neomycin, GI 
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bleeding prevention) should be instituted. Use of antibiotic needed 
if there is evidence of infection e.g. fever, abdominal pain, 
monitoring and treatment of electrolytes abnormality required, 
vitamin K useful in DCLD. 
ANTIFIBROTIC THERAPY  
1) Colchicine: Microtubule inhibitor, it‟s a relative less side 
effect drug, only complication being diarrhea, and some 
efficacy in preventing progression of Cirrhosis.  
2) Steroids: Useful in autoimmune hepatitis, if DF more than 32 
indication of steroid use if there is no contraindication of 
steroid.  Otherwise has no role in therapeutics of alcohol 
cirrhosis.  
3) Interferon: Efficacy not proven in ALD. Useful in case of 
chronic viral hepatitis  
SERUM ZINC LEVEL IN DCLD PATIENT.
61, 62, 64
 
Zinc is an important trace element that required essentially 
for body growth and development, also has important role in 
activation of many enzymes, Zinc is a co-factor for these enzymes. 
Zn level in DCLD patient usually low .possible causes of zinc 
deficiency in DCLD. Due to poor intake of Zn, malnutrition, low 
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protein diet, excessive loss of Zn through GI tract. Mostly  zinc in 
body present bound form ,it may loosely bound with albumin and 
tightly associated with α2-globulin ,significantly Albumin level low 
in DCLD patient
4
 , patients  who have more low serum albumin 
concentration also prone for more zinc deficiency ,low albumin 
level is one of most important cause of zinc low level in DCLD , 
other cause of low zinc level in DCLD patient are loss of appetite 
,patient of  DCLD .patient of cirrhosis usually have anorexia and 
malnutrition due to poor dietary intake also one reason of low Zn , 
Available Zn also not useful due to lack of albumin. Diuretics are 
important part of treatment of DCLD patient, The excess use of 
diuretic also increase the urinary secretion of Zn. frequent bowel 
wash and lactulose also increase GI loss of zinc ,low zinc level 
affects  more than 300 enzymatic system of  body ,Zn is important 
co-factor for urea cycle enzymes and has great role in conversion of 
ammonia to urea ,due to deficiency of zinc urea affect the brain that 
can cause neurological disturbance in DCLD patient
69,70 
,That 
called as hepatic encephalopathy , patient those has HE also has 
more low serum zinc , Zn deficiency one of precipitating factor for 
HE . 
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Due to Zn low concentration many skin manifestations also 
occur in DCLD patient may has growth retardation and 
hypogonadism. Loss of immunity also can occurs due to zinc 
deficiency that all are associated with poor prognosis, 
ZINC   
Zinc is an essential trace element and plays an important role 
not only in catalytic reaction but also in the maintenance of 
structural integrity of protein by forming zinc finger like structure 
created by chelation centre including cysteine and histidine 
residues and regulation of gene expression. 
ZINC STRUCTURE 
 
Figure: 7- Zinc structure 
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HISTORY 
72
  
Zinc was found  metallic form zinc ore were used for making 
brass and zinc compounds were used for healing wound and eye 
sores    first isolated pure zinc discovered by Andreas Sigsimund 
Marggarf. 
 Brass a zinc alloy was produced by the romans in the time of 
Augustus [20BC -14AD ]  Charaka Samhita thought to have been 
written in 500BC or before mention which oxidized, The produces 
pushpanjan zinc mines at Zawar  near Udaipur in India have been 
active since Mauryan period The smelting of metallic zinc here to 
have begun around the 12
th
 century AD Biological role of zinc was 
recognized by Raulin in 1869 2a ,He observed that zinc was 
required for aspergillus niger growth , In 1934 zinc role in rat as 
essential element proved,   
Chemistry 
73
- Zinc second most abundant micro element in 
body, Zn [atomic weight -65.39 and atomic no-30] lies at end of 
first transition series ZN
+2
 a stable ion with complete 3D electron 
shell, zinc is excellent electron acceptor with no redox reaction, has 
fast legend exchange kinetics and flexible Co- ordination geometry 
One hypothesis says that zinc ions present in cytoplasm at 10-
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11mol/L and Zn also present in metelloenzymes and transcription 
factor
74
  
 Dietary sources
75
 – Zinc is a widely distributed in non 
vegetarian diet, mainly protein bound form, the most available 
source are red meat and fish .  
For vegetarians bean and wheat germ are good source but Zn 
content can be reduced by milling and food processing, 
Distribution
77 – an adult weighing 70kg  has 1.4 to 2.3 gm 
zinc in body it is distributes various parts of body in following 
order; 
1) Skin and prostate;70-80mg /100gm (Highest) 
2) In kidney, liver, muscles, heart ,pancreas and spleen ; 
2.3to5.5mg/100gm  
3) Brain and lung;1.4to1.5mg/100gm 
ZN absorption, metabolism and excretion – Daily intake of 
zinc 12 gm/day in normal adult ,about 20% part of total intake  
absorption by GI tract  but low intake condition absorption can be 
increase up to 100%, these measurement made by stable Zn tracer 
to assess Zn homeostasis and plasma Zn kinetic. 
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Estimation of Zn absorption has also been compared by using 
different isotope techniques, the absorption of zinc from diet is 
inhibited by dietary phytate, fiber, oxalate copper and iron; some 
drug also reduced Zn absorption,  
The absorbed zinc come to the liver by portal circulation 
where active integration into metalloenzyme and plasma protein as 
albumin andα2microglobin. 
Blood plasma has less than 1%of the total body zinc and 
present in marrow concentration 80-120 micro/dl  ~80% of plasma 
zinc bound with albumin and rest Zn tightly bound with α2 
macroglobulin.    
Zinc in plasma in poise with plasma aminoacid [histidine and 
cysteine] and that small ultra filterable percentage may important in 
cellular in take mechanism, 
Total body zinc at least 1.4 -2.3 gm , it is present in the cell 
of all active tissue organ, about ~55% in muscle, 30 in prostate, 
semen ,and retina and bone ,RBC(red blood cell) Zn present in form 
carbonic anhydrase , so Zn in RBC 10% high compare to plasma , 
Fecal excretes both unabsorbed dietary Zn and remove from gut , 
total excretion about 10-15 mg/dl, o.5% Zn remove by urine, zinc 
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excretion increase during catabolic illness and also increase in 
starvation , as a result remove from skeleton muscle and excretion 
of Kenton bodies
78 
 
Requirement ; Zn for normal health has been recommended 
0.2 mg  Zn per kg body weight , Adult man and woman need 15 to 
20 mg day , during pregnancy and lactation require 25mg  Zn daily.  
Function of zn
73,77 
; 
More than 300 Zn contained metalloenzyme in all six 
categories of enzyme system, as example Alkaline phoshatase , 
carbonic anhydrase, RNA and DNA polymerases, carboxypeptidase 
and alcohol dehydrogenase. 
The important role of zinc protein and nucleic acid synthesis , 
explain the failure of growth and wound healing observed in 
individual with Zn deficiency ,Protein can from domain which bind 
with tetrahedral zinc atom by co-ordination with histidine and 
cystein  and form a folded structure that known as „ Zinc Finger‟ 
,which is a biologically active units have main  role in gene 
expression by acting as DNA –binding transcriptor factor and play 
key role in development biology and Zn also regulate steroid , 
thyroid and other hormone synthesis  
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Zinc bind with metal response factor MTF-1 and actives 
metalloprotein [Mt] expression , that multifunction low molecular 
weight protein has high cystein which reversible bind zinc ,MTF-1 
is important intracellular Zn trafficking and help to balance 
intracellular Zn concentration ,Storage and secretion of insulin;   
Secretary vesicles  of pancreatic beta cell which stored insulin as 
crystalloid like hexamers , each stable by binding with Zinc to thiol 
or imidazole side chain amino acid of insulin ,Elimination of free 
radical ; as a co-factor of superoxide dismutase(cytoplasmic). Zn 
plays main role removal oxide free radical by SDM
79
 
Role in Alzheimer disease-Both Zn deficiency and toxicity 
precipitated Alzheimer disease, excess Zn bind to peptidase site of 
amyloid  
Taste sensation- Zn protein gluten has role gustatory 
function
80
  
Role in vita A metabolism ; Zn has role to stimulate the 
release of vitamin A from hepatic cell to blood and increase vita A 
in plasma , also its utilization in rhodopsin synthesis,  Role in 
growth and development; Zinc deficiency lead to hypogonadism 
and dwarfism , Zn concentration notice less in plasma RBC ,urine 
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and stool in such patient‟s deficiency decrease spermatogenesis in 
male and menstrual cycle are disturbed in female  Zn deficiency 
due to phyrate rich diet can cause poor body growth , failure of 
puberty and hypogonadism in human, 
Role in wound healing;   
Zinc high concentration has been found in granulation tissue 
in and around the healing wound, 
Role in biosynthesis of mononucleotide-    
The synthesis of mononucleotide and their integration in to 
nucleic acid has been found to be impaired in Zn deficiency, 
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HEPATIC ENCEPHALOPATHY 
Hepatic encephalopathy is a serious and common 
complication of liver disease, potentially reversible, or progressive 
complication associated neurological and psychological disturbance 
of brain function, known as a brain functions alteration 
neuropsychiatric syndrome.
1,2  
It is characterized by brain functions alteration lead to cognitive 
dysfunction, behavior abnormality and changes in personality transient 
neurological symptoms and characteristic EEG (electroencephalographic) 
low frequency with high amplitude patterns can be present with acute and 
chronic liver failure. Hepatic encephalopathy is associated with severe 
liver insufficiency  ,The characteristic manifestations are wide range of 
neurological and psychiatric symptoms loss of orientation ,loss of 
working memory(WM), visuospatial disturbance , changes in personality 
as irritability ,lack of interest , emotion disturbance , decrease physical 
activity , abnormal sleep cycle pattern ,day time sleeping observed ,motor 
system like decrease tone increase deep tendon reflex , bilateral planter 
extensor , flapping tremor may occur advanced stages of HE, the 
development of acute encephalopathy with an progressive  sudden 
worsening   in the level of consciousness, presented  as severe confusion 
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,stupor or coma.
85,86
 Usually some precipitating factor are identified with 
acute encephalopathy, for  treatment of the episode is directed towards 
the removal of the precipitating cause . Once the causative factors are 
treated successfully the encephalopathy disappears, patient recover to 
previous state. However, if patients with end stage liver disease has less 
reserves of liver function the hepatic encephalopathy may be a persistent 
condition. The low hepatic function reserve causes spontaneous chronic 
HE. those patient have multiple portal-systemic anastomosis 
,therapeutically created TIPS also important cause of persistent HE  
There is mostly  a precipitating factor for HE , such patient present with 
episodic HE, once precipitating factor like dehydration ,UGI bleeding, 
constipation  occur patient redevelop hepatic and brain dysfunction and 
the diagnosis and treatment should base on  such aspects related to 
precipitant. Chronic hepatic encephalopathy may be manifest as recurrent 
episodes of acute encephalopathy known as chronic-episodic 
encephalopathy or associated with persistent neurological disturbance 
may be prominence of neurological manifestations. In clinical practice, 
distinction is difficult because acute episodes occur with the chronic-
persistent encephalopathy. The difference between the two forms is 
subjective and is reflected in the chronic presentations, if the 
manifestations are mild, we can use term “recurrent encephalopathy”. On 
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the other aspect, if the manifestations are chronic and severe, the term 
“persistent encephalopathy” should be used. In patients who present with 
chronic recurrent HE, episodes can be associated with a precipitant factor 
but generally are spontaneous or related to the end stage of treatment. It is 
frequently occur that these episodes are attributed due to constipation. An 
episode acute on chronic in encephalopathy usually occur has an abrupt 
onset and recovered fast with termination of precipitating factors. 
Between episodes, the patient may be conscious and alert and not any 
signs of cognitive function loss, unless he or she is examined for minor 
hepatic encephalopathy by construction aprexia or neuropsychological 
Testing.  
 
Figure: 8- patient with minimal hepatic encephalopathy unable to 
copy above star and figures, difficulty in writing also present.
1
 
Pyramidal and /or extra pyramidal signs may present with 
persistent encephalopathy, seizure uncommonly reported with HE                                
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PATHOGENESIS OF HE;
 1,96,97,98,100,101
 
For many years, controversy about the pathology is there 
about the production of the toxic substances which is causative for 
the altered cerebral state. There has been always consideration 
about the role of ammonia, GABA , synergic toxins or endogenous 
benzodiazepines in the development of hepatic encephalopathy.  
There are peripheral multi-systemic dysfunctions, and changes in 
the intercellular transmission in brain, produced by changes in 
astrocytes.  Key role in pathogenesis in HE are neurotoxin 
produced by gut, dysfunction of astrocytes, brain water 
homeostasis, disturbance of neurotransmitters, oxidative stress and 
inflammation in brain and infection                                            
PERIPHERAL SYSTEMS  
1. Intestinal  
There is debate for the role of H. pylori, ammonium produces 
by these bacteria in the GIT, ammonia has key role in the 
development of HE. Some studies trial demonstrated a high 
prevalence of the infection H.pylori in patient with alcoholic 
hepatitis, as well as individuals with cirrhosis and chronic HE.  
But it seems role of micro organisms in the development of HE may be 
low.  
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2. Liver failure:  
Hepatic failure is one of the important cause for the 
development of hepatic encephalopathy, resulting from reduced 
liver functional activity that reduces the clearance of ammonium, 
high blood levels of ammonium is responsible for clinical 
manifestations HE.  
3. Portal-systemic shunting:  
 Congenital portal-systemic shunts in children, presented with 
hepatic encephalopathy, even without hepatic disease. Also, patient 
of DCLD with portal-systemic shunts prone for HE.  
4. Muscle:  
 Poor muscle mass and loss nutritional status in DCLD 
patients prone for the complication like HE. Muscle wasting 
associated with increase of TNF-α, which stimulates transcription 
factors e.g. NK-a, resulting in decreased synthesis of myosin 
protein.  Poor muscle mass reduces capacity of muscle in 
detoxification of glutamine and ammonium, resulting that patient 
can present with high ammonia level lead to hepatic 
encephalopathy.                       
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BRAIN ALTERATIONS:  
1. Cerebral water homeostasis  
Researches have been shown that osmotic changes in brain 
with hepatic failure lead to cerebral edema. Whenever the brain 
develops edema, intra cerebral pressure will increase and lead to 
herniation in brain that can cause coma or death.   
Glutamine produced in astrocytes due to detoxification of 
ammonium in the astrocytes because there is no urea cycle in brain 
and that glutamine increase the entry of water into brain cells leads 
to edema in the astrocytes.
100  
 
2. Brain axonal communication; 
There is also clue of the vital function of astrocytes in 
maintaining  
 
Figure: 9-MRI images T1- or T2-Weighted showing bilateral, 
symmetrical hyper intensity in pallidus.
91
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Normal axonal activity in HE there is no change in the 
neurons morphology. The Alzheimer type II brain cells (astrocytes) 
can show abnormalities-decreased activity of transporters 
(glutamate), and increased monoamine oxidase (MAO) activity and 
increased role of benzodiazepine receptor, As a result alterations 
into communication between astrocytes and other brain cells. For 
example brain astrocytes synthesized neurosteroids which activates 
endogenous benzodiazepines receptors and GABA receptors  
OTHER IMPORTANT HYPOTHESES 
1. Gut –induced neurotoxins 
There are neurotoxins produced by gut hypotheses have 
important key role related to the pathogenesis of HE: most 
important cause of ammonia production in intestine due to break 
down of diet protein, 
• Ammonium.96, 97 
Ammonium is main central role to the pathogenesis of hepatic 
encephalopathy.  Ammonia turn out  mainly  from protein of food 
and micro organism action in colon, normal person ammonia 
usually goes to peri portal hepatocytes and converted to urea by  
urea cycle and few ammonia change to glutamine by venous 
hepatocytes ,serum ammonia level increase due to ammonia 
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forming bacteria in gut ,shunting of portal hepatic system, poor 
function of liver cell, low serum zinc ,decrease muscle mass  Brain  
intake of ammonia raised in DCLD patient ,in brain no urea cycles 
there ammonia  detoxification  by the astrocytes many neuron-
chemical changes occur astrocytes. There are many other factors 
that interact with ammonium in brain, causing alterations in the 
brain cell ( cytokine elevations, hyponatremia ,low zinc level in 
serum and changes in the legends of astrocytes), there by producing  
neuron-chemical activity  which  increase the occurrence of HE.   
 
Figure: 10-Gut induced neurotoxin and sources 
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Further studies consistent with accumulation of toxic levels of 
ammonia in HE is given by the results of recent studies using (PET) 
Positron Emission Tomography. The PET studies revealed that the 
increased cerebral metabolic rate for ammonia in patients with HE was 
accompanied by an increase in the permeability / surface area product, a 
measure of blood brain barrier permeability suggesting that in hepatic 
insufficiency the barrier becomes highly accessible to ammonia.  
2. Role of zinc in clearance of ammonia; 
Zinc is an important key element of many physiological 
mechanisms, important co-factor of many urea cycle enzymes like 
ornithine transcarbomylase, glutamine synthetase and with advanced 
class of cirrhosis and increasing HE class the zinc level in blood also 
decrease. Low serum and liver Zn decrease the activity of ornithine trans 
carbamylase in liver. due to disturbance urea cycle  cause increase the 
ammonia level in blood and raised ammonia level and low zinc level 
associated with HE and malnutrition ,patient  those more sever HE also 
has more low plasma zinc,  
3. Role of Endogenous benzodiazepine;                                                                        
The role of endogenous BZD in the changes of GABA-ergic 
neurotransmission is not clearly understood. Trials with flumazenil 
have not shown significant results.  
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Figure: 11- Normal urea cycle in human 
 
 52 
 
Figure: 12-Ammonia; Key role in hepatic encephalopathy and it’s 
main sources• 
4. Change in brain neurotransmitters   
Excitatory NT decrease in brain mainly due to high 
ammonium. Branched chain amino acids (BCAA) decrease in 
DCLD patient that can increase the entry of other amino acids in to 
brain. Those amino acids are pre source of other brain transmitters 
that affects Glutamine formation.   
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BCAA is of important role in ammonia clearance, that the 
amino acids have a direct role in ammonia detoxification in muscle, 
increasing. Many other brain transmission cycles also affected 
development of HE,  
1) Serotonin (5-HT)-increase in HE 
2) Catecholamine-reported low in patient dye due to HE 
3) Acetylcholine- low 
4) Other e.g. opioids, steroid, melanin, histamine 
 Most of cirrhosis have poor nutrition due to malnutrition and 
low oral intake that patient may have microelements and vitamins 
deficiencies, those are also additive factors to turn of events like 
recurrent HE. 
For example zinc deficiency have important role in 
development of HE.   Zinc supplementation a dose of 600 mg/day 
for short period useful in improvement in HE. Many studies have 
been suggested role of zinc in recovery HE.  
4. Microorganism over growth;  
However, some studies suggested that colonization of 
bacteria in gut has been suggested role in development to MHE, but 
still it is not clear, need more studies.  
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Conclusion, pathogenesis of HE due chronic or acute liver 
cell failure, collection of gut derived toxin and portal-systemic 
shunt. 
 The precipitating key factor (absence specific cause) is an 
increase level of serum ammonium. The pathogenic mechanism 
includes the production of false neurotransmitters, facilitated 
sensibility of neurons by γ-amino butyric acid (GABA), increases 
in the plasma endogenous benzodiazepines, failure of urea cycle 
due to low enzymes activity as a result of low level of zinc in 
plasma and excessive manganese deposits on the basal ganglia.   
 CLINICAL CLASSIFICTION OF HE  
Generally, we can diagnose overt HE easily, but for diagnosis 
of minimal hepatic encephalopathy (MHC) need neuropychometric 
test.  
Clinical symptom based stages as shown below stage- II 
shows symptoms such as moderate confusion and more behavioral 
abnormality, in stage- I minimal behavioral changes may be 
present, like mild confusion, euphoria or mild depression. In 
advanced HE stages patients may be present with global confusion, 
drowsy and unconscious state. 
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Also some non specific changes in electroencephalographic (EEG) 
can be found (triphasic waves and delta activity).  
 Categorization HE on the basis of etiological causes  
Type-A:  Acute onset hepatic failure  
Type-B:  Due to shunting Portal-systemic without intrinsic 
liver disease (more frequent)  
Type-C: As result of PHT and DCLD with Porto-systemic shunts  
Classification and grades of hepatic encephalopathy according 
severity of clinical manifestation;  
Grade 0-Minimal hepatic encephalopathy (MHE);  
Neuropsychometric and psychological test need to diagnosis 
of MHE, changes occur in test.  
Patient not have clinical symptom. 
Construction aprexia may present  
Grade I- Loss of awareness,  
Anxiety or euphoria or depression, 
Low attention, 
Monotonous voice  
Sleep cycle disturbances.   
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Grade II- Apathy and Lethargy and/or confusion. 
Not orientation about time,   
Asterixis, triphasic waves may be on EEG  
Grade III- Severe confusion/ irrelevant speech,/incoherent 
language 
Drowsy but responds to stimuli 
Asterixis, triphasic waves on EEG  
Grade IV- Coma, initially can respond to painful stimulus 
Later no responds to deep pain and Delta wave in EEG  
 
Figure: 13 -flapping tremor in HE 
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Factor associated with precipitation of HE; 
The hepatic encephalopathy is one of common complication of DCLD. 
The cirrhosis patient developed complication like HE due to presence of 
various precipitating factors. 
Table 2-precipitating factors of HE. 
1, 93, 94
  
Nitrogen product Drug Metabolic Others 
GI Bleeding Diuretics  Hypokalemia  Infection  
Constipation  Opiates  Hypontremia  Renal failure  
High protein  Sedative  Alkaiosis  Surgery  
Azotamia  Diazepam  Dehydration  Hepatopathies  
H.Pylori  Phenol  Low zinc  Magnese  
Uremia  Hepatotoxic  Hyperkalemia  Short fatty acid 
Microorganism   Hypoxia  
 Episode of hepatic encephalopathy possibly occur as result 
of one or more precipitating factor, as described above table.  
 Hepatic encephalopathy most common precipitating factor is 
UGI bleeding and infection. 
The clinical course of HE on the basis on frequency and form 
of occurrence of HE in the same patient can be present as like hood 
three types:  
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Episodic HE-Acute onset 
  Associated with precipitating factors                                                           
  Recurrent encephalopathy; 
  When patient again present with in 6 month or less time.  
Persistent HE: 
Cognitive disturbance  
Extra-pyramidal manifestations,  
Sleep-pattern changes that can be either mild or severe, 
But always continuous 
4. Minimal HE:  
Sub-clinical cases,  
Diagnosis by psychometric score  
HE is manifested in different forms and may be occurred with 
some neurological manifestations, can be present with focal 
deficits.  
Usefully, clinical features are contributes due to cerebral 
edema. 
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 That brain edema associated with the clinical picture HE and 
high mortality in the patients with HE. 
Table:3 The Glasgow Coma Score (GCS) - For diagnosis of 
unconscious level 
Variable 
Score 
Eye opening 
Motor 
response 
Verbal response 
1. Spontaneous  Follow oral 
com 
Fully orientation 
2. To oral 
command 
Localized pain Disorientation  
3. To pain Withdrawal to  
pain  
Moderate confusion  
4. No  Abnormal 
flexion  to pain 
Severe confuse 
(incomprehensive) 
5.  Extensor 
response to 
pain 
No response to 
commands 
6.  No response   
Poor  attention and changes of brain state may occur as 
behavior abnormality , memory disturbance, confusion, semi coma 
and to coma; also, occurred with various of n signs include a 
rigidity ,abnormal reflexes increase DTR ,extensor planter ,astrexis  
and rarely, convulsions.  
The earliest sign of encephalopathy is a disturbance in the 
sleep cycle. High ammonium concentration is a key factor in the 
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diagnosis of HE. But   the predictive value of ammonia is very less 
in DCLD patients, 
 Ammonia level in arterial blood with adjustment ammonia 
value with pH we can increase predictive value of ammonia, but 
these tests may not be possible in all center. 
Recently, some studies have shown association   between 
ammonia level in arterial blood and its correlation with 
development of brain herniation in FLF.  
 Few other studies have suggested that more ammonium level 
(>300 mg/dl) found in advanced hepatic encephalopathy (stages III 
and IV), these patients are associated with brain herniation. 
 High ammonia level in blood not associated with change in 
liver function  Also, it has been shown by many study that 
ammonium levels  correlate with the severity of HE but not 
associated the with treatment response. Brain imaging also 
important role in diagnose MHE stage I and stage II Brain MRI can 
demonstrate basal ganglia manganese deposition and showing 
globus pallidus
. 90
 
Computed tomography in advanced HE usually shows 
presence of atrophy or brain edema. Positron emission tomography 
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studies images reflecting physiological and biochemical changes in 
brain processes.  
Finally, MRI spectroscopy suggests evident the rising 
glutamine spike in brain and low choline and myo-inositol.  
NEUROPSYCHOLOGICAL FOR MHE.
91, 92
 
1) Line drawing  
2) Numeric connection  
3) Digital symbols and  
4) Points following.  
These test called PHES Psychometric hepatic encephalopathy 
score (PHES) and should be complete in ten minutes.  
The objective is to evaluate the reaction time and the visual 
construction, accusiocity, memory, concentration testing across 
neuropsychological domains is possibly the optimal  approach to 
identify selective abnormalities in areas such as attention and fine 
motor function.  
However the need for shorter evaluations has led to the use of 
four tests in most case. A specific test like the line tracing, the 
NCT, the serial dotting tests has a good specificity for HE 
compared with other encephalopathy. 
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Figure: 14- Psychometric test for MHE; Pencil and paper test, 
Digital symbol test, and Line tracing; 
NEUROPHYSIOLOGIC TESTS:  
 Electroencephalogram (EEG) 
 Evoked potentials 
Both, the EEG and evoked potentials, can be used for the 
detection of minimal HE, on principle. Because of the more 
sophisticated technical requirements of evoked potential studies the 
EEG has been used, predominantly. The major finding is a general 
decrease in wave frequency and an increase in wave amplitude. 
First, so called theta waves with a frequency between 4 - 7 cps 
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occur, and then these theta waves predominate and are committed 
by delta waves with a frequency of 1 - 3 cps, Completely there is 
loss of wave amplitude and a flattening of the curve. These 
abnormalities are not restricted to manifest encephalopathy but may 
be found even in cirrhotic without clinical signs of encephalopathy. 
It must be emphasized, that there is no close correlation between 
the grade of HE and the degree of EEG abnormalities.  
Compared to psychometric tests the sensitivity of the EEG for 
the diagnosis of minimal HE is limited. The EEG is useful for 
follow up examinations. Predominantly Clinical improvement in 
patients with HE is often preceded by an increase in EEG 
frequency, while on the other hand an impending HE episode may 
be foreseen when the EEG frequency of a patient decreases. This is 
true even if a patient with an individual frequency of 12 cps for 
example presents with an 8 or 9 cps EEG, which is within the 
normal range per definition but is undoubtedly pathological, 
compared to the patients individual standard frequency.  
Finding in EEG and evoked responses are nonspecific and not 
useful in diagnosis of HE. The simplest assessment in hepatic 
encephalopathy is to grade the degree of abnormality of the 
conventional tracing.
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Figure: 15- Changes in EEG in patient with HE with present in 
different stages 
MANAGEMENT AND THERAPY OF HE:  
The treatment of DCLD patients with overt HE includes 
establishing the treatment protocol. In recurrent HE the main 
objectives are avoid the acute episodes, while a patient with chronic 
HE our aims are towards improvement in quality of life and 
persistent symptoms.  
The treatment of HE should be added with the treatment of 
the other complications of DCLD.  
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In DCLD patient‟s presence complication HE is indication of 
poor prognosis and hence should be keeping as candidates for liver 
transplantation.
33  
Routine  treatment aims for patients with HE is the 
importance of applying some general supportive  measures to 
patient  like protection of air way, nursing care, bed care ,proper 
feeding   during the period of unconscious and abnormal mental 
state,.  
 It is very essential to pick up the acute precipitating factors 
and treat them aggressively.
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TREATMENT AIMS  
 Correction of precipitating factors  
Proper management of HE needs identification and aggressive 
treatment of precipitating etiology. Mostly the precipitating 
incident is either UGI bleeding or infection. Some other 
precipitating factors listed above include excess protein load 
dietary intake, drugs acting on brain acting as sedatives, analgesics, 
and dehydration or electrolyte disturbance.  
Laboratory and radiologic investigations can also help in 
identifying precipitating factors. 
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 Dehydration should  be treat  by stop of diuretics and 
adequate   IV fluids.38  
 GI bleeding can be treating with blood transfusion. Long term 
treatment for variceal bleeding are- 
 Endoscopic sclerotherapy (ES) 
 Endoscopic variceal ligation (EVL) 
 Drug use treatment for variceal bleeding;, 
 Octriotide 
 Terlipressin     
The patient with massive ascites   paracentesis should be 
performed and send for cell count, culture and gram staining to 
evaluate for spontaneous bacterial peritonitis (SBP).  
 Infection patients of HE with fever and abdominal pain 
suggestive infection should evaluate for SBP   and start with 
antibiotics treatment. Practice guidelines for ascites management 
have included standardized methods for the fluid tap technique and 
for ascitec fluid analysis. Some studies have been shown that 
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clinical risk factors for infection and recurrent SBP suggestive 
antibiotic prophylaxis.  
Recently trial in DCLD patient use of albumin and 
cefotaxime compared with antibiotic alone was associated with 
significant improvements in survival rate and renal function among 
selected patients. 
Hypokalemia should be treated with oral or IV potassium.  
 HE precipitated by dietary protein intake so diet should be balanced 
for patient with DCLD and use sedatives avoid in patients with HE,  
D/D OF HEPATIC ENCPALOPATHY;
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Table4- differential diagnosis of HE 
 
We should exclude as well other causes of abnormal barin 
function  
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 MEDICAL THERAPY: 
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Nonabsorbable disaccharides: 
102
  
There are lactulose and lactitol.  Role of these agents in 
treatment of HE is to decrease the ammonia production and 
absorption in GI tract, 
Lactulose act via three mechanisms; 
1) Laxative effect- these agents increase the movement of 
ammonia from the portal circulation into the colon, and 
interference with the uptake of glutamine by the intestinal 
mucosa and its subsequent metabolism to ammonia.  
2) Increase uptake of ammonium by microorganism 
3) Decrease production of ammonia-By change the glutamine 
uptake via intestinal mucosa. 
Lactulose- as syrup with dosages of 10 to 30ml given 3 times 
a day. Patient should pass 2 to 3 soft bowel movements daily.  
Lactulose given by mouth reaches the large intestine in caecum, where it 
is broken by bacteria mainly to lactic acid that lead to raised osmotic 
volume of the colon, low fecal pH. 
 69 
Promote the growth of lactose fermenting bacteria e.g. 
bacteroids, which are use ammonia and suppressed ammonia 
forming bacteria. The colonic fermentative bacteria prefer lactulose 
to blood when both are present. Side effects of lactulose are 
diarrhea and intestinal pain, fluctuance.  
Non absorbable disaccharides are the first line therapy for 
treatment of acute HE and improvement in symptoms occurs in 
more than 80% cases. A placebo controlled trial showed lactulose 
successfully improve MHE cognitive function or quality of life in 
DCLD patients with minimal hepatic encephalopathy.  
Lactitol- is a second generation disaccharide easily produced 
in chemically pure crystalline form and available as powder. It is 
not broken down or absorbed in the small intestine, but is 
metabolized by colonic bacteria. A dose of 20-100 gram/day is well 
tolerated and effective 
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Figure: 16 –nonabsorble disaccharides metabolism  
in intestine by        bacteria 
Antibiotics: 
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Neomycin and Metronidazole decrease production of 
ammonia in intestine by acting against bacteria. 
Neomycin- is used for short period due to its side effects on 
long term use (4-6 gram daily in divided doses).  
Metronidazole -200mg three times a day per oral is as 
effective as neomycin. Prolonged use leads to dose related nervous 
system toxicity.  
Rifaximin: It is an oral antibiotic with fewer side effects and no 
known drug interactions. Poorly absorbed (<1%) .It has been found very 
safe and highly effective in patients with stage I to II HE. 
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 A  blind controlled study compared Rifaximin 1200 mg per 
day to Neomycin 4 gram per day, after 21 days of treatment the 
symptoms of HE and serum ammonia levels were  reduced in both 
group, although reduction in serum ammonia  were significantly 
greater with Rifaximin. 
Another study Rifaximin 1200 mg/d compare with lactitol 60 
g/d administered for 2 weeks showed significantly improvement in 
80% symptoms of both groups.  
Zinc role in treatment of HE: 
61,62
  
Is an essential trace element which plays an important role in 
the regulation of protein and nitrogen via urea cycle As a co-factor 
of many enzymes use in urea cycle, Zinc deficiency has been 
implicated in the pathogenesis of hepatic encephalopathy as 
decreased serum zinc levels and low zinc level associated with in 
inverse correlation with blood ammonia levels in those patients. 
Zinc short term therapy improved ammonia clearance via urea 
cycle, that decreased serum ammonia level in cirrhosis patient and 
improve his/her  neurophychiatric manifestation. A double blind 
randomized placebo controlled study of zinc acetate 600 mg/d for 7 
days demonstrated improved mental status that was associated with 
increase in serum zinc levels.47 In another study after 3 months of 
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supplementation with 600 mg zinc sulfate daily there was 
normalization of serum zinc levels and improvement in 
neuropsychiatric testing  in hepatic encephalopathy .  
OTHER THERAPIES:  
Benzodiazepine receptor antagonists:  
In a study of cirrhotic patients, IV Flumazenil was compared 
with placebo. The intervention group showed improvement in 
neurological scores in 18% of patients with stage 3 HE and 15% of 
those with stage 4 HE, as opposed to 4% and 3% of placebo treated 
patients respectively.  
LOLA (Ornithine L-Aspartate) 
105
  
LOLA has been demonstrated to reduce blood ammonia levels 
by providing substrates for the intracellular conversion of ammonia 
to urea and glutamine.  
Sodium benzoate  
It may be beneficial in the treatment of hepatic 
encephalopathy by increasing urinary excretion of ammonia. 
Probiotics:  
Probiotics are defined as biologically live microorganism 
dietary agents. These are effective in HE on the host beyond their 
nutritive value. The mechanism of action of probiotics in HE is 
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achieved to be the change the substrates for potentially pathogenic 
microorganism, and the aim of fermentation end products for 
potentially beneficial bacteria.  
BCAA (Branched chain amino acids) . 
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DCLD patients usually have low plasma BCAA, which have 
role in change in brain transmitter, needs more studies. 
Nutrition:  
Guidelines given by the European Society for Nutrition and 
Metabolism suggested that patients with cirrhosis should have an 
energy intake of 30 to 40 kcal/kg body weight per day and daily 
protein intake of 1.3 to 1.5 gram per kg body weight. 
 The concept of protein restriction diet for the treatment of 
HE was based on old uncontrolled studies made nearly 50 years 
past. 
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MATERIAL AND METHODS 
This crossection study was conducted in Institute of Internal 
Medicine at Rajiv Gandhi Government General Hospital and 
Madras Medical College,Chennai 
Duration of study -6 months(April 2014 to September 2014) 
Sample Size-75 cases 
Inclusion Criteria 
 patients diagnosed as Decompensated Chronic Liver 
Disease presents with Hepatic encepalopathy. 
 Including minimal HE 
 DCLD due to all etiology  
 Age >20 years 
 Both sex 
 Written informed consent 
Exclusion Criteria- 
 Metabolic causes of encepalopathy  
 Altered sensorium due to head injury and stroke 
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 Psychiatric disorders  
 Alcohol with drawal state 
 Acute alcohol intoxication 
Data Collection  
Study subjects are both sex group and above the 20 year age. 
DCLD pateints admitted with complication hepatic encepalopathy , 
The diagnosis of  HE based on history taken according to a 
Questionnaire, a detailed clinical history of  subjects taken 
regarding present and past illness.Quetions asked about altered 
sleep pattern anxity depression,euphoria,altered sensorioum 
dysoriention and cofusion,history about pracifitating factors also 
taken like UGI bleedin,fever ,diarrhea ,abdominal pain abdominal 
distension,constipation ,jaundice, malnutrition and high protein 
diet. 
Datail clinical examination for sign of liver faliure like Ictrus, 
Pallor, Spider nevi,Palmer erythema,clubbing ascitis and pittng 
edema 
Persional history for alcohol intake and duration of alcohol 
abuse,drugs abuse and smoking. 
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Grading of  HE by 
 Clincal history , 
 PHES(Psychometric hepatic encepalopathy score), 
 Astrexis 
 WHC(West hevan classification) 
 GCS(Glaow coma score) 
Clinical grading of HE 
Table 5-WHC Grade of HE 
Grade Clinical sign and symptoms 
MHE Alteration in psychometric test ,construction aprexia  
with out clinical manifestations 
Grade-I Loss of awareness 
Euphoria or anxiety 
Lack of concentration 
Altered sleep pattern 
Grade-II Lethargy, slurred speech 
Disorientation for time,persnality changes ,Astrexis 
Grade-III Drowsy, Confused 
Respond to stimuli 
Bizarre behavior 
Grade-IV Coma  
Not respond to pain 
 
 77 
For each pateints blood investigations 
 Serum zinc level 
 Complet blood counts 
 Liver function test 
 Renal function test 
 PT/INR 
All pateints also classified by Child’s score based on following 
paramitters- 
Table-6 Modified Child‟s classification  
 
Total score=15 
5-6==A 
7-9 ==B 
9-15 ==C 
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Method use for Serum Zinc estimation- 
Reagents = 
 Diathizone-100 ml diathizone(0.1%) was mixed with 
100ml of 0.1ml NaOH preoared daily for use 
 Pottasium iodide powder 
 Trichloro acetic acid 
 Saturated Tris solution 
 HCL 6N=60 ml of acid diluted with 100ml water  
 NaOH 4N=40 grams NaOH in 100ml of water 
 Standerds solution of Zinc     
Principle –Dithizone (fresh prepration) froms a yellow 
coloured complex with Zinc tris and buffered tricholoro acetate 
with centrifugated serum. Other minor elements separated by 
insoluble iodine and HCl before complex formation of Zinc.that 
yellow coloured complex measured by spectrophotometry.  
Procedure- Three test tube were used and marked as standard, 
blank and unkown. 3ml standard zinc solution in standard,3ml 
distilled water in blank and 3ml sera in unknown tube in pipetted, 
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mixed and kept in room tempreture for 10 min and centrifuged at 
3600 rpm for half hour after that and 0.3ml of 10N NaOH added 
and kept stand for 10 min.all supernatant transferred to separete 
tube and mixed 0.5ml 0f HCl and 0.5ml of diathizone reagent . The 
yellow colour formed and read at 555nm after 5 min. 
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DATA ANLYSIS AND OBSERVATION 
Table 1-Sex distribution 
 
 
Figure 1 -sex distribution 
In our study total 75 cases, including 72 (96%) and 3 female 
(4%).  Hepatic encephalopathy more common in male (96%) 
 Frequency Percent 
Male 72 96.0 
Female 3 4.0 
Total 75 100.0 
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Table-2 Age group distribution 
 Frequency Percent 
< 30year 0 0 
30-50year 47 62.7 
>50 year 28 37.3 
Total 75 100.0 
 
 
Figure -2 Age distribution 
In our study hepatic encephalopathy more common in middle 
age group between 30-50 year age (63%) 
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Table3- Mortality during the course of treatment in hospital 
 Frequency Percent 
Recovered 70 93.3 
  Expired 5 6.7 
 
 
Figure: 3- outcome distribution 
In our study 5% mortality in hepatic encephalopathy during 
the course of treatment 
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Table4- Etiology of cirrhosis 
 Frequency Percent 
Alcohol 68 90.7 
HBV 3 4.0 
Alcohol and HBV 3 4.0 
Wilson  disease 1 1.3 
 
 
Figure:4- Etiological distribution of cirrhosis 
In our study most common cause of cirrhosis is Alcohol 
(90%). 
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Table5-Duration of alcohol intake in alcohol related DCLD 
patient 
 
 Frequency Percent 
Nil 3 4.0 
>= 10 65 86.7 
5-10 7 9.3 
Total 75 100.0 
 
 
Figure5 –Duration of alcohol intake 
In our study 87% patient consumed alcohol more than 10 year 
duration in Alcohol related DCLD 
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Table6- Common presenting compliant in DCLD patients with HE 
Presenting Feature Patient 
Fever  28 
Abdominal pain 42 
Vomiting  12 
Diarrhea  7 
Constipation  41 
Ascites  61 
Bleeding  34 
Pedal edema 49 
Disorientation  41 
Confusion  14 
Coma  4 
 
Figure: 6-presenting features in DCLD patient with HE 
In our study most common presenting complain of patient 
ascites other Common features given in table. 
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PRECIPITATING FACTOR OF HEPATIC 
ENCEPALOPATHY 
Table7- precipitating factors in hepatic encephalopathy 
Precipitating factor Patients 
Infection  28 
UGI bleeding 34 
Constipation  41 
Diarrhea  7 
Hyponatremia  29 
Hypokalemia  13 
Hyperkalemia  9 
Diueretic  21 
 
Figure:7-distribution of precipitating factors 
 In our study common precipitating factors is constipation and 
UGI Bleeding. 
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DISTRIBUTION OF PATIENTS ACCORDING WHC 
CLINICAL GRADE  
Table8- patient according WHC Grading 
 Frequency Percent 
MHE 10 13.3 
Grade I 26 34.7 
Grade II 24 32.0 
GradeIII 11 14.7 
Grad IV 4 5.3 
 
Figure: 8- Distribution of patient according WHC Grading 
In our study maximum patients are in grade-I and grade-II (35 
&32). 
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SERUM ZINC LEVEL IN VARIOUS GRADE OF HE 
Table9- Serum Zinc level in various WHC grade  
  
S. Zn 
Total 
60-69 50-59 40-49 30-39 < 30 
WHC MHE Count 7 2 0 1 0 10 
    % within 
WHC 
70.0% 20.0% .0% 10.0% .0% 100.0% 
  Grade I Count 1 8 16 0 1 26 
    % within 
WHC 
3.8% 30.8% 61.5% .0% 3.8% 100.0% 
  Grade II Count 0 2 9 12 1 24 
    % within 
WHC 
.0% 8.3% 37.5% 50.0% 4.2% 100.0% 
    % within S. 
Zn 
.0% 16.7% 36.0% 50.0% 16.7% 32.0% 
  Grade III Count 0 0 0 9 2 11 
    % within 
WHC 
.0% .0% .0% 81.8% 18.2% 100.0% 
  Grade IV Count 0 0 0 2 2 4 
    % within 
WHC 
.0% .0% .0% 50.0% 50.0% 100.0% 
 
Count 8 12 25 24 6 75 
% within 
WHC 
10.7% 16.0% 33.3% 32.0% 8.0% 100.0% 
All DCLD patients have Zn deficiency, low zinc significantly 
associated With higher grade of HE  
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Figure: 9- Serum Zn level (60-69µg/dl) in various grade of HE   
Maximum patients in MHE in this zinc level group 
 
 
Figure10- Serum Zn level (50-59µg/dl) in various grade of HE 
Maximum patients in WHC grade-I in this zinc level group 
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Figure: 11- Serum Zn level (40-49µg/dl) in patients with  
various grade of HE 
 
 
Figure: 12- Serum Zn level (30-39µg/dl) in patients presented 
with various grade of HE   
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Figure: 13- Serum Zn level (<30µg/dl) in patients with various 
grade of HE 
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Figure: 14 –distribution of HE grade according serum Zn level 
In our study statistically significantly association low zinc 
values and higher grades of hepatic encephalopathy (p-value 0.001) 
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SERUM ZINC LEVEL IN VARIOUS CHILD PUGH CLASS 
Table10-Comparison of serum zinc level with Child pugh class 
  
S. Zn 
Total 60-
69(I) 
50-
59(II) 
40-
49(III) 
30-
39(IV) 
< 
30(V) 
CPC Class A Count 6 2 1 0 0 9 
    % within 
CPC 
66.7% 22.2% 11.1% .0% .0% 100.0% 
  Class B Count 2 6 10 6 0 24 
    % within 
CPC 
8.3% 25.0% 41.7% 25.0% .0% 100.0% 
  Class C Count 0 4 14 18 6 42 
    % within 
CPC 
.0% 9.5% 33.3% 42.9% 14.3% 100.0% 
Total Count 8 12 25 24 6 75 
  % within 
CPC 
10.7% 16.0% 33.3% 32.0% 8.0% 100.0% 
 
Figure15- Serum Zn level (60-69µg/dl) in patients with various 
child pugh classes 
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Figure16- Serum Zn level (50-59µg/dl) in patients with  
various child pugh 
 
Figure17- Serum Zn level (40-49µg/dl) in patients with various 
child Pugh classes   
 
 94 
 
Figure18- Serum Zn level (30-39µg/dl) in patients with various 
child Pugh classes 
 
 
Figure19- Serum Zn level (<30µg/dl) in patients with various 
child Pugh 
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Figure20- Comparison of serum Zn level and Child Pugh score 
In our study low serum Zn level have statistically significant 
association with higher child-Pugh score (p-value 0.001). 
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Table 11– Comparison between serum Zn level and  
serum Albumin level 
 S. Zn 
Total 
60-69 50-59 40-49 30-39 < 30 
SA 3.5-5.0 
gm/l 
Count 
4 2 2 2 0 10 
    % 
within 
SA 
40.0% 20.0% 20.0% 20.0% .0% 100.0% 
  2.5-3.5 
gm/l 
Count 
4 9 21 15 5 54 
    % 
within 
SA 
7.4% 16.7% 38.9% 27.8% 9.3% 100.0% 
  < 2.5 
 gm/l 
Count 
0 1 2 7 1 11 
    % 
within 
SA 
.0% 9.1% 18.2% 63.6% 9.1% 100.0% 
Total 
Count 8 12 25 24 6 75 
% 
within 
SA 
10.7% 16.0% 33.3% 32.0% 8.0% 100.0% 
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Figure21- Albumin level in patient with serum Zn (60-69µg/dl) 
 
 
Figure22- Albumin level in patient with serum Zn (50-59µg/dl) 
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Figure23- Albumin level in patient with serum Zn (40-49µg/dl) 
 
 
Figure24- Albumin level in patient with serum Zn (30-39µg/dl) 
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Figure25- Albumin level in patient with serum Zn (<30µg/dl) 
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Figure26- Comparison between serum Zn level and  
serum Albumin level 
In our study patients had low serum albumin statistically 
association with low level of serum Zn (p-value 0.029). 
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DISCUSSION 
A cross sectional study done in 75 patients is diagnosed in 
DCLD with hepatic encephalopathy, conducted at Rajiv Gandhi 
Government General hospital Chennai. 
Hepatic enc 
 
302ephalopathy is one of the most serious and common 
complications in DCLD patient presented in hospital.(1) 
In developing countries most common etiology in cirrhosis 
patients is viral hepatitis and second alcohol (1,2). In our study 
maximum cases develop cirrhosis due to Alcohol abuse (90% cases) 
and second viral hepatitis. 
4,82  
 
In our study Male population more dominantly affected to 
DCLD with encephalopathy. 
83
 
Most commonly affected middle age group (19,81). In our 
study 63% cases were middle age between 30 to 50 year age group.    
DCLD patients present as HE, majority of them identified 
clear precipitating factors. There are many factors have role in 
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precipitation in hepatic encephalopathy, common precipitating 
factors are constipation, infection and UGI bleeding. 
81, 84 
UGI bleeding is most common factor according Sheila Sherlock. 
Zinc level significantly low in DCLD 
71
, one study done by 
Kaushik and colleagues also same result. 
 Our study all DCLD patients admitted as complication HE 
,had low serum zinc level. Patient who presented in worse grade 
HE, those found more drops in serum Zn that is clear in this study 
that low serum Zn significantly associated with high class of 
hepatic encephalopathy. 
Zinc is important co-factor for many enzymes. Zn has key 
role in physiological detoxification of ammonia via urea cycle in 
liver and as a co factor in ornithine Transcarbamylase (OTC)  so 
low zinc level associated with decreased OTC activity and higher 
plasma concentration of ammonia.   low plasma  Zn impairs 
nitrogen cycle in muscle and increase glutamine in blood. As result 
in advanced grade in HE significantly more drop in plasma Zinc 
(1). Short term oral Zinc supplement is very useful as an adjunct 
treatment in DCLD patient with hepatic encephalopathy
63
. 
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 In our study serum zinc level significantly low in higher 
grade of hepatic encephalopathy.   Study done at Egypt by Mohsen 
Maher and collegue had similar result. 
In this study, compression between serum Zn and stage of 
liver disease, Zinc level significantly low in worse class of 
cirrhosis,(4,71) in DCLD patient other factor like malnutrition, 
poor oral intake and diuretic use also related to low Zn level.  
Serum Zinc (>80%) bound loosely with albumin, serum 
albumin concentration obviously decreased in DCLD patients. In 
our study low albumin level associated more drops in serum Zn.  
This study also indicates low serum Zn level may be contributed by 
significant low serum albumin concentration  
 
LIMITATIONS OF STUDY 
Further studies with adequate sample size and extended 
period are needed to confirm our study in DCLD patients with 
hepatic encephalopathy. 
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SUMMARY 
 Hepatic encephalopathy is common and serious complication 
in DCLD patient admitted in hospital. 
 Most common presenting complaint is acitis, other common 
are altered sleep pattern and disorientation. 
 Common precipitating factors are constipation, infection and 
UGI bleeding.  
 Male population predominantly affected. 
 Common in middle age group (30-50 year) 
 Alcohol abuse (>10 year duration) is common etiology in 
cirrhosis patients. 
 All DCLD patient presented in HE had low serum Zinc level ( 
<70 µg/dl), Zn deficiency significantly correlated with higher 
grade of HE. 
 Patient who is in advanced class of DCLD had significant low Zn 
level most of patient in child class C had Zn level (30-39 µg/dl). 
 Low albumin level in DCLD markedly associated with 
decrease plasma Zn level. 
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CONCLUSION 
From this study all patients in DCLD with complication 
Hepatic encephalopathy identified low serum Zinc; it is associated 
with higher grade of HE. 
More drops in serum Zn is correlated with worse grade of HE. 
Low serum zinc is an indirect precipitating factor in HE.  
Short term Zn supplement may be useful in prevention and 
treatment in HE patients. 
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PROFORMA 
SERUM ZINC LEVEL IN DECOMPENSATED LIVER 
DISEASE AND ITS CORRELATION WITH THE STAGE OF 
HEPATIC ENCEPHALOPATHY 
Name:      Patient IP No: 
Age /Sex:                                     Contact No: 
PRESENTING SYMPTOM  
Abdominal pain, Fever                              Abdominal distension                            
Vomiting                                                Diarrhea                                                 
Constipation  Loss of appetite  
Loss of weight   Jaundice  
Fever  UGI bleeding 
Urine out put Leg swelling  
Sleep pattern  Disorientation  
Speech  Anxiety  
Confusion  Coma  
Fetor hepatics   
PAST HISTORY  
Jaundice                                             HT 
DCLD                     DM 
Other Neurological disease 
 
PERSONAL HISTORY 
Alcohol – amount and duration 
Smoking  
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GENERAL EXAMINATION  
Level of conscious: 
Pallor: 
Ictrus: 
Pedal edema: 
Clubbing: 
Parotid enlargement: 
Spider angioma: 
Palmar erythema: 
Acites : 
Skin manifestations: 
BP: 
PR: 
Weight: 
Height: 
SYSTEMIC EXAMINATION 
Abdomen   
Dilated vein 
Distension  
Organomegaly  
CNS  
Level of conscious 
Number correction test (NTC) 
Construction aprexia 
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GCS Score 
 Sleep pattern 
Flapping Tremor 
 
RS 
CVS 
INVESTIGATION  
Total Bilirubin(mg/dl) 
AST (IU/L) 
APT (IU/L) 
AP (IU/L) 
Total Protein (gm/l) 
Serum Albumin (gm/l) 
Blood urea (mg/dl) 
Serum creatinine (mg/dl) 
Serum electrolytes (meq/l) 
Serum Zinc 
Total WBC count  
Platelets count  
Prothrombin Time 
INR 
Ultrasound abdomen 
Portal Doppler 
  
  



   
KEY TO MASTER CHART; 
 
Sex; abdomen distension            clubbing ; 
        male-1                                                           yes-1 
        yes -1 
        Female-2                                                        no-2  no-2 
 
Out come; UGI Bleeding; Spleen; 
                Recovered -1 
                 Yes-1 yes-1 
                    Expired -2 no-1 no-2 
 
Etiology of DCLD/HE; Anorexia- liver; 
      Yes-1 yes-1 
   Alcohol -1 no-2 no-2 
        HBV-2 
        HCV-3 Malnutrition;  fector hepaticus ; 
Wilson  disease-4   Yes-1        yes-1 
Other -5                                               no-2 no-2 
 
Fever ; Ictrus-                         construction aprexia 
 Yes-1 
Yes -1 yes -1 no-1 
No-2 no-2 
 
Abdominal pain  Pedal edema(PE) Sleep alteration  
 Yes-1 
Yes -1 yes -1 
No-2 no-1 
No-2 
Vomiting ; spider nevi; Asterixis ; 
 Yes-1 yes -1 
Yes -1 no-2 no-2 
No-2 
Diarrhea ; palmar erythema ; Confusion ; 
 
Yes-1 yes -1 yes -1 
No-2                                                    no-2 no-2 
 
Constipation ;                                  parotid enlargement  Coma; 
 Yes -1 yes-1 yes-1 
No-2 no-2 no-2 
  
West haven grading Clild –Pugh class             serum protein;       
MHE-1 classA-1                            
Grade-1-2 class B-2 decreased-1 
Grade II   -3 class C-3 normal(6.5-8)-1 
Grade  III   -4 
Grade  IV  -5 AST 
Serum zinc(in  microgm/dl)            elevated-1              serum albumin (3.5-5)  
70-150  -1 normal-2 normal(3.5-5)-1 
60-70-2 2.5-3.5=2 
50-59-3 ALT- less than 2.5=3 
40-49-4 elevated-1 
30-39-5 normal-2 
Less than30-6 
 
Total bilirubin(mg/dl) SAP serum urea= 
Less than2=1 elevated-1            elevated=1 
2-5mg/dl=2 normal-2 normal=2 
More than 5 
 
Serum creatinine(1.3 serum Na
+ 
 Serum K(3.5-5) 
Elevated=1 more than 150 meq/l-1 
  More than 5=1 
Normal=2 normal135-150meq/l=2 normal(3.5-5)=2 
 
 Less135meq/l=3 less 3.5meq/l=3 
  
Total cell count ; Age group- 
(Leucocytosis ≥11000;) 
≥50 year=1 
Yes -1 
   30-50yr=2 
No-2 
 ≤30 year=3 
 
Platlets count ; 
(Thrombocytopenia 1lakh) Duration of alcohol intake 
 
Yes-1 ≥10 year=1 
 
No-2 5-10year=2 
 
 ≤5year=3 
PT/INR;(≥1.71) 
 
Prolonged -1 
 
Not-2 
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1 71804 47 1 1 1 1 1 2 2 1 1 1 1 2 1 1 2 2 1 2 1 2 2 2
2 71694 42 1 1 1 1 1 2 2 2 1 2 1 2 1 1 2 2 2 2 2 2 2 2
3 74478 60 1 2 1 1 2 1 2 1 1 2 1 1 1 1 2 2 1 1 1 2 1 1
4 74990 45 1 1 1 2 2 2 2 2 1 2 1 1 2 2 2 2 2 1 1 2 2 2
5 76681 35 1 1 1 1 1 2 1 2 1 1 1 2 1 1 2 2 2 1 2 2 1 2
6 76970 49 1 2 1 1 2 2 2 1 1 1 1 1 1 1 2 2 1 1 2 2 1 1
7 79734 69 1 2 1 1 1 2 2 1 1 1 1 1 1 1 1 1 2 2 1 2 1 1
8 79633 43 1 1 1 2 2 2 2 2 1 2 1 2 1 2 2 2 2 1 1 2 2 2
9 82074 43 1 1 1 1 1 2 2 1 1 1 1 2 1 1 1 1 2 1 1 1 1 2
10 82164 40 1 1 1 2 2 2 2 1 1 2 1 1 2 1 2 2 2 1 2 2 2 2
11 82238 38 1 1 1 1 1 1 2 2 1 1 1 1 1 1 2 2 2 2 2 2 2 1
12 82199 73 1 2 1 2 1 1 1 2 1 1 1 1 2 2 2 2 2 1 1 2 2 1
13 84684 46 1 1 1 2 2 2 2 1 1 1 1 2 1 1 2 2 1 1 1 2 2 2
14 84717 47 1 1 1 2 1 2 2 1 1 2 1 1 1 1 3 2 1 2 2 2 2 2
15 84723 65 1 1 1 2 2 2 1 2 1 2 1 1 2 1 2 2 2 1 1 1 2 2
16 84850 47 2 1 4 1 1 2 2 2 1 2 1 2 1 1 2 2 2 2 1 2 2 2
17 83507 67 1 1 1and2 2 1 2 2 1 1 2 1 1 1 2 2 2 2 2 1 2 1 2
18 83087 34 1 1 1 1 1 1 2 1 1 1 1 2 1 1 2 2 2 2 2 2 2 2
19 82206 47 1 1 1 1 1 2 2 1 1 1 1 2 1 1 2 2 2 2 2 2 2 2
20 84612 59 1 1 1 2 2 2 2 2 1 2 1 1 1 1 2 2 2 2 1 2 2 2
21 84110 38 1 1 1 1 2 2 2 2 1 2 1 2 1 1 2 2 2 2 2 1 2 2
22 84095 36 1 1 1and2 2 2 2 2 1 1 2 1 1 1 1 2 2 2 2 1 2 2 2
23 85385 53 1 1 1 2 2 2 2 2 1 1 1 1 1 1 2 2 2 1 1 2 1 2
24 86370 59 1 1 1 2 2 2 2 1 1 1 1 1 2 2 2 2 2 2 1 2 2 2
25 85358 55 1 1 1 2 1 2 2 1 1 2 1 1 2 2 2 2 1 1 1 2 2 2
26 84669 66 1 1 1 2 1 2 2 1 1 2 1 1 1 1 2 2 2 2 2 2 2 2
27 84828 52 1 1 1 2 2 2 2 1 1 1 1 2 1 1 2 2 1 1 1 2 1 2
28 84888 34 1 1 1 1 1 2 2 1 1 1 1 2 1 2 2 2 2 2 1 1 1 2
29 85183 68 1 1 1 2 2 2 2 1 1 2 1 1 1 1 2 2 2 1 1 1 2 2
30 85562 55 1 1 1 2 1 2 2 2 1 2 1 1 1 1 2 2 2 2 1 2 2 2
31 80334 32 1 1 1 2 2 1 2 2 1 1 1 2 1 2 2 2 1 2 1 1 2 2
32 84831 48 1 1 1 2 1 1 2 2 1 1 1 1 2 2 2 2 2 2 1 2 2 2
33 84311 58 1 1 1 1 1 2 1 2 1 1 1 1 2 2 2 1 1 1 2 2 2 2
34 84277 30 1 1 1 1 1 2 2 1 1 2 1 2 1 2 2 2 2 1 1 2 2 2
35 84135 49 1 1 1 2 2 2 2 1 2 1 1 1 1 1 2 2 2 1 2 2 1 2
36 82238 38 1 1 1 1 1 2 1 2 2 1 1 2 1 1 2 2 1 2 1 2 1 2
37 82199 73 1 1 1 2 1 2 2 1 1 2 1 1 1 1 2 2 2 1 2 2 1 2
38 82164 83 1 1 1 2 1 2 2 1 1 2 1 2 2 2 2 2 2 2 1 1 2 2
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39 84975 50 2 1 2 1 1 2 2 1 1 2 1 1 1 2 2 2 2 2 2 1 2 2
40 85206 36 1 1 1 2 1 1 2 2 1 1 1 1 1 2 2 2 2 2 2 1 2 2
41 85890 52 1 1 1 2 1 1 1 2 1 2 1 1 1 2 2 2 2 1 2 2 2 2
42 83866 55 1 1 1 2 2 2 1 2 1 2 1 1 2 2 2 2 2 1 2 1 2 2
43 86022 56 1 1 1 2 1 2 2 1 1 1 1 2 1 1 2 2 1 1 1 2 1 2
44 86448 48 1 1 1 1 1 2 2 1 1 2 1 1 1 1 2 2 2 1 2 2 2 2
45 87015 47 1 1 1 1 1 2 2 1 1 2 1 1 1 1 2 2 2 2 2 1 2 2
46 87216 56 1 1 1 2 2 2 2 1 1 1 1 2 1 1 2 2 2 2 1 2 2 2
47 87255 49 1 1 1 2 2 2 2 1 1 2 1 1 1 1 2 2 2 2 1 2 1 2
48 87201 38 1 1 1 1 1 1 2 2 2 2 1 2 1 2 2 2 2 2 1 1 2 2
49 87271 49 1 1 1 2 2 2 2 1 1 1 1 1 1 2 2 2 2 1 1 2 1 2
50 87290 52 1 1 1 2 1 2 2 1 1 2 1 1 1 1 2 2 2 2 2 2 2 2
51 89771 48 1 1 1 2 2 2 2 1 1 2 1 1 1 1 2 2 2 2 2 2 2 2
52 90024 40 1 1 1 1 1 2 2 2 1 1 1 1 1 1 2 2 2 2 2 1 2 2
53 89187 50 1 1 1 1 2 2 2 1 1 2 1 1 1 1 2 2 2 1 1 2 2 2
54 88008 49 1 1 1 2 2 2 2 2 1 2 1 1 2 2 2 2 2 2 2 2 2 2
55 90472 46 1 1 2 1 1 2 2 2 1 2 1 2 1 2 2 2 2 1 1 1 2 2
56 91718 47 1 1 1 1 1 2 2 2 1 1 1 1 1 1 2 2 2 2 1 1 2 2
57 90551 62 1 1 1 2 2 1 2 2 1 1 1 2 1 2 2 2 2 2 1 2 2 2
58 89599 44 1 1 1 2 2 2 2 1 1 1 1 2 2 2 2 2 2 2 2 2 2 2
59 89686 55 1 1 1 2 2 2 2 1 1 2 1 1 1 1 2 2 2 2 1 2 2 2
60 91507 51 1 1 1 2 1 1 2 2 1 1 1 1 1 2 2 2 2 2 1 2 2 2
61 90804 37 2 1 2 2 2 1 2 2 1 1 1 1 1 2 2 2 2 2 2 1 2 2
62 90271 45 1 2 1 1 1 2 2 1 1 2 1 1 2 1 2 2 2 2 1 2 1 2
63 90280 43 1 1 1 2 1 2 2 1 1 1 1 1 1 1 2 2 2 2 2 2 2 2
64 90073 45 1 1 1 1 1 2 2 2 2 2 1 1 1 1 2 2 1 2 2 2 2 2
65 89271 51 1 1 1 2 1 2 2 2 1 2 1 1 1 1 2 2 2 2 2 2 1 2
66 90613 48 1 1 1 2 1 2 2 2 1 2 1 1 1 1 1 2 2 2 2 2 2 2
67 90640 50 1 1 1 2 1 2 2 1 1 1 1 2 1 1 2 2 1 2 1 2 2 2
68 91858 41 1 1 1and2 2 2 2 2 1 1 2 1 1 2 2 2 2 2 2 2 1 2 2
69 91915 58 1 1 1 2 2 2 2 2 1 2 1 1 2 2 2 2 2 2 1 2 2 2
70 92431 42 1 1 1 1 2 2 2 1 1 2 1 1 2 1 2 2 2 2 2 2 2 2
71 92724 55 1 1 1 2 2 2 2 2 1 2 1 1 1 1 2 2 1 2 2 2 2 2
72 92283 43 1 1 1 2 2 2 2 2 1 1 1 1 1 1 2 2 1 2 1 2 2 2
73 92408 55 1 1 1 2 1 2 2 1 1 2 1 1 1 1 2 2 2 2 1 2 2 2
74 92583 32 1 1 1 1 1 2 2 2 1 1 1 1 1 1 2 2 1 2 2 2 2 2
75 92635 42 1 1 1 2 2 2 2 1 1 1 1 1 1 1 2 2 1 2 2 1 2 2
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2 1 1 2 2 2 2 2 3 3 3 1 1 1 2 2 2 2 3 2 2 2 2 2 1 2 1
2 1 2 2 2 2 2 1 1 2 2 2 2 2 1 2 2 2 3 2 2 2 1 2 1 2 1
1 2 1 2 1 1 1 5 3 6 3 1 1 1 1 3 1 1 3 3 1 1 1 1 1 1 1
2 1 2 2 2 2 2 1 2 3 2 2 2 2 1 2 2 2 2 2 2 2 2 2 1 2 1
2 1 1 1 1 2 2 3 3 5 3 1 1 1 1 3 1 1 3 2 1 1 2 2 1 2 1
1 2 2 2 2 1 1 5 3 5 3 1 1 2 1 2 1 1 3 3 1 1 1 1 1 2 1
1 2 2 2 1 1 1 5 3 5 3 1 1 1 1 3 1 1 2 3 1 1 1 1 1 1 1
2 1 1 2 2 2 2 2 2 3 2 2 2 2 1 2 2 2 2 2 2 1 2 2 1 2 1
2 1 1 1 1 2 2 3 3 5 3 1 1 1 1 3 2 2 3 2 2 1 1 1 1 2 1
2 1 2 2 2 2 2 1 2 5 1 2 2 2 1 2 2 2 2 2 2 1 2 2 1 2 1
1 1 1 1 1 1 2 4 3 5 3 1 1 1 1 2 1 2 3 2 1 1 1 1 1 2 1
1 1 1 2 2 2 2 2 3 4 2 2 2 2 2 2 2 2 2 3 2 1 2 2 1 1 1
2 1 1 1 1 1 2 4 3 6 3 2 1 1 2 2 2 2 3 3 2 1 2 2 1 2 2
2 1 1 1 1 2 2 3 3 5 3 1 2 2 2 1 1 1 3 2 2 1 1 1 1 2 1
2 1 1 2 2 2 2 2 3 6 1 1 2 2 1 2 1 1 2 3 1 2 2 2 1 1 1
2 1 1 1 1 2 2 3 3 5 3 2 2 2 1 3 1 2 3 2 2 1 1 1 1 2 no
2 1 1 1 1 2 2 3 3 5 3 1 1 1 1 2 1 2 2 2 2 1 1 1 1 1 1
2 1 1 1 1 2 2 3 3 4 3 1 2 2 1 3 1 2 3 2 2 1 2 1 2 2 2
2 1 1 2 2 2 2 2 3 3 3 1 1 2 1 2 1 1 2 1 1 2 2 2 1 2 1
2 1 1 2 2 2 2 2 3 4 2 2 2 1 2 1 2 2 2 2 2 1 2 2 1 1 1
2 1 1 1 2 2 2 2 3 4 3 1 1 1 1 1 2 2 2 2 1 1 2 1 1 2 1
1 1 1 1 1 2 2 3 3 4 2 1 1 1 1 2 2 2 2 2 2 2 2 2 1 2 1
2 1 1 1 1 2 2 3 3 4 3 1 2 2 2 2 2 2 3 3 2 1 1 1 1 1 1
2 1 1 2 2 2 2 2 1 3 2 2 2 2 1 2 2 2 2 1 2 1 2 2 1 1 1
2 1 1 2 2 2 2 2 2 4 1 2 2 2 1 2 2 2 2 2 1 2 2 2 1 1 1
2 1 1 2 2 2 2 2 2 4 2 2 2 2 1 2 1 2 2 2 2 2 2 2 1 1 1
2 1 1 1 1 1 2 4 3 5 3 1 1 1 1 3 2 2 3 3 2 1 1 1 1 1 1
2 1 1 1 1 1 2 4 3 6 3 2 2 2 1 2 2 2 2 2 1 1 1 1 2 2 2
1 2 1 1 1 2 2 3 3 5 3 1 1 2 1 2 2 2 2 2 2 2 2 2 1 1 1
2 1 1 2 2 2 3 3 5 3 1 1 2 1 2 2 2 2 2 2 2 1 2 1 1 1 1
2 1 1 1 1 1 2 4 3 5 3 1 2 2 1 2 2 2 2 2 2 1 2 2 1 2 2
2 1 1 2 2 2 2 2 2 3 2 1 2 2 2 1 2 2 2 2 2 1 1 1 1 2 1
1 1 2 2 2 2 2 3 4 3 2 2 2 1 2 1 2 3 1 2 1 1 1 1 1 1
1 1 1 1 2 2 3 3 3 3 1 1 1 1 2 1 1 3 1 1 2 1 1 1 2 2 2
2 1 1 1 1 2 2 3 2 4 2 1 2 1 2 2 2 2 3 2 2 2 2 1 1 2 1
2 1 1 1 1 1 2 4 3 5 3 1 1 1 1 2 1 1 3 3 2 1 1 1 1 2 1
2 1 1 1 1 2 2 3 3 5 3 2 2 2 1 2 2 2 3 1 2 2 2 2 1 1 1
2 1 1 2 2 2 2 2 2 3 2 2 2 2 1 2 2 2 2 2 2 2 2 2 1 2 1
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2 1 1 1 2 2 2 2 2 3 2 2 2 2 1 3 2 2 2 2 2 2 2 2 1 2 no
2 1 1 1 1 2 2 3 3 4 2 2 2 2 1 2 1 1 3 1 1 2 2 1 1 2 1
2 1 1 1 1 2 2 2 3 4 3 1 2 2 1 2 2 2 2 2 2 1 1 1 1 1 1
2 1 2 2 2 2 2 1 1 2 1 2 2 2 2 1 2 2 2 2 1 2 2 2 2 1 1
2 1 1 1 1 2 2 3 3 4 3 1 1 1 1 2 1 1 3 1 1 2 1 1 1 1 1
2 1 1 1 1 2 2 3 3 4 3 1 1 2 1 2 1 2 2 3 1 1 1 1 1 2 1
2 1 1 2 2 2 2 1 2 2 2 1 2 1 2 2 2 2 2 2 2 2 2 2 1 2 1
2 1 1 1 1 1 2 4 3 5 2 1 2 1 1 2 2 2 2 2 2 1 1 1 1 1 1
2 2 2 1 1 1 2 4 3 5 3 1 2 1 2 1 1 1 3 3 1 1 2 2 1 2 1
2 2 2 2 2 2 2 1 2 2 3 1 1 2 1 2 2 2 2 2 1 2 2 1 1 2 2
1 2 1 1 1 1 1 5 3 6 3 1 1 2 1 2 2 2 3 3 2 2 1 1 1 2 1
2 1 1 1 1 1 2 4 3 5 3 1 1 2 1 3 2 2 3 1 2 1 1 1 1 1 1
2 1 1 2 2 2 2 2 2 4 3 1 1 1 1 2 2 2 2 2 2 1 2 2 1 2 1
2 1 1 2 2 2 2 2 3 4 3 1 1 1 1 2 2 2 2 2 2 1 2 2 1 2 1
2 1 1 1 1 2 2 3 2 5 2 2 2 2 1 2 2 2 2 2 2 1 2 2 2 1 1
2 1 2 2 2 2 2 2 1 2 1 2 2 2 2 1 2 2 2 2 2 1 2 2 2 2 1
2 1 1 1 2 2 2 2 2 4 3 2 1 1 1 2 2 2 2 2 2 1 1 1 2 2 1
2 1 1 2 2 2 2 2 3 4 3 2 2 2 1 2 1 1 2 2 1 1 1 1 1 2 1
2 1 1 1 2 2 2 2 1 4 2 2 2 1 2 3 2 2 2 2 2 2 2 2 1 1 1
2 1 1 2 2 2 2 1 1 2 2 2 2 2 2 1 2 2 2 2 2 2 2 2 2 2 1
2 1 1 1 2 2 2 2 3 4 3 1 1 1 1 2 2 2 3 2 2 2 2 2 1 1 1
2 1 2 2 2 2 2 1 1 2 1 2 2 1 2 1 2 2 2 2 2 2 2 2 1 1 1
1 2 2 2 2 2 2 1 1 2 2 1 1 1 2 2 2 2 2 2 1 1 2 2 2 2 no
2 1 1 1 1 1 2 4 2 5 2 2 2 1 1 3 2 2 3 2 1 1 1 1 1 2 1
2 1 1 1 1 2 2 3 2 5 3 2 2 2 1 2 2 2 2 2 2 1 2 2 1 2 1
2 1 1 2 2 2 2 2 2 4 3 2 2 2 1 2 2 2 2 2 2 2 2 2 2 2 1
2 1 1 1 1 2 2 3 3 5 3 1 2 2 1 2 2 2 2 2 2 1 1 1 1 1 1
2 1 1 1 1 2 2 4 2 5 2 2 2 1 2 2 1 2 3 2 2 1 1 1 1 2 1
2 1 1 1 2 2 2 2 2 4 3 1 1 1 1 2 2 2 2 2 2 1 1 1 1 2 1
2 1 1 1 1 2 2 3 2 5 2 2 2 1 2 2 2 2 2 2 2 2 2 2 1 2 1
2 1 1 2 2 2 2 2 2 4 2 2 2 2 2 2 2 2 2 2 2 2 2 2 1 1 1
2 1 1 1 1 2 2 3 2 4 1 2 2 2 2 2 1 2 3 2 2 1 2 2 1 2 1
2 1 1 2 2 2 2 1 1 3 1 2 2 2 2 2 2 2 2 2 2 1 2 2 1 1 1
2 1 1 2 2 2 2 2 2 4 3 2 2 2 1 2 2 2 2 2 2 2 2 2 2 2 1
2 1 1 1 1 2 2 3 3 4 3 1 1 1 1 2 2 2 3 3 1 1 1 1 1 1 1
2 1 1 1 1 2 2 3 3 5 3 1 1 1 2 2 1 2 3 1 1 2 2 2 1 2 2
2 1 1 2 2 2 2 2 2 3 2 2 2 2 1 2 2 2 3 2 2 1 2 2 1 2 1
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 135 
Table – comparison between Zn deficiency and WHC grade of HE 
Chi-Square Tests 
 Value df 
Asymp. Sig.  
(2-sided) 
Pearson Chi-Square 93.134(a) 16 .001 
Likelihood Ratio 89.697 16 .001 
Linear-by-Linear Association 42.311 1 .001 
N of Valid Cases 75   
Table- comparison serum Zn with Child score 
Chi-Square Tests 
 Value df 
Asymp. Sig.  
(2-sided) 
Pearson Chi-Square 44.938(a) 8 0.001 
Likelihood Ratio 40.301 8 .001 
Linear-by-Linear 
Association 
29.617 1 .001 
N of Valid Cases 75   
Table- comparison of serum albumin with serum Zn 
Chi-Square Tests 
 Value df 
Asymp. Sig.  
(2-sided) 
Pearson Chi-Square 17.127(a) 8 .029 
Likelihood Ratio 15.377 8 .052 
Linear-by-Linear 
Association 
9.772 1 .002 
N of Valid Cases 75   
 
